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Bipolar disorder (BP) is a complex psychiatric disorder characterized by 
episodes of mania and depression. BP affects approximately 1% of the world’s 
population and shows no difference in lifetime prevalence between males and 
females. BP arises from complex interactions among genetic, developmental 
and environmental factors, and it is likely that several predisposing genes are 
involved in BP. The genetic background of BP is still poorly understood, although 
intensive and long-lasting research has identified several chromosomal regions 
and genes involved in susceptibility to BP.
The results of this study provide evidence for the involvement of several 
candidate genes and genomic regions in the genetic aetiology of BP and related 
cognitive impairments in the isolated Finnish population. This study supports 
the view that BP results from the effects of multiple rare variants and that there 
are only a few common variants that can be unequivocally identified in various 
study populations, and supports the use of different phenotypic subtypes, 
such as cognitive traits or the presence of psychotic symptoms, to capture the 
underlying genetic mechanism of BP.
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Abstract
Outi M. Palo. Genetic Background of Bipolar Disorder and Related Cognitive 
Impairments. National Institute for Health and Welfare (THL), Research 29, 140 
pages. Helsinki 2010. ISBN 978-952-245-243-6 (print); 978-952-245-244-3 (pdf)
Bipolar disorder (BP) is a complex psychiatric disorder characterized by episodes of 
mania and depression. BP affects approximately 1% of the world’s population and 
shows no difference in lifetime prevalence between males and females. BP arises 
from complex interactions among genetic, developmental and environmental 
factors, and it is likely that several predisposing genes are involved in BP. The 
genetic background of BP is still poorly understood, although intensive and long-
lasting research has identified several chromosomal regions and genes involved in 
susceptibility to BP. 
This thesis work aims to identify the genetic variants that influence bipolar 
disorder in the Finnish population by candidate gene and genome-wide linkage 
analyses in families with many BP cases. In addition to diagnosis-based phenotypes, 
neuropsychological traits that can be seen as potential endophenotypes or 
intermediate traits for BP were analyzed. 
In the first part of the thesis, we examined the role of the allelic variants of 
the TSNAX/DISC1 gene cluster to psychotic and bipolar spectrum disorders and 
found association of distinct allelic haplotypes with these two groups of disorders. 
The haplotype at the 5’ end of the Disrupted-in-Schizophrenia-1 gene (DISC1) 
was over-transmitted to males with psychotic disorder (p = 0.008; for an extended 
haplotype p = 0.0007 with both genders), whereas haplotypes at the 3’ end of DISC1 
associated with bipolar spectrum disorder (p = 0.0002; for an extended haplotype 
p = 0.0001). The variants of these haplotypes also showed association with different 
cognitive traits. The haplotypes at the 5’ end associated with perseverations and 
auditory attention, while the variants at the 3’ end associated with several cognitive 
traits including verbal fluency and psychomotor processing speed. 
Second, in our complete set of BP families with 723 individuals we studied 
six functional candidate genes from three distinct signalling systems: serotonin-
related genes (SLC6A4 and TPH2), BDNF -related genes (BDNF, CREB1 and 
NTRK2) and one gene related to the inflammation and cytokine system (P2RX7). 
We replicated association of the functional variant Val66Met of BDNF with BP 
and better performance in retention. The variants at the 5’ end of SLC6A4 also 
showed some evidence of association among males (p = 0.004), but the widely 
studied functional variants did not yield any significant results. A protective four-
variant haplotype on P2RX7 showed evidence of association with BP and executive 
functions: semantic and phonemic fluency (p = 0.006 and p = 0.0003, respectively).
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Third, we analyzed 23 bipolar families originating from the North-Eastern 
region of Finland. A genome-wide scan was performed using the 6K single nucleotide 
polymorphism (SNP) array. We identified susceptibility loci at chromosomes 7q31 
with a LOD score of 3.20 and at 9p13.1 with a LOD score of 4.02. We followed 
up both linkage findings in the complete set of 179 Finnish bipolar families. The 
finding on chromosome 9p13 was supported (maximum LOD score of 3.02), but 
the susceptibility gene itself remains unclarified.
In the fourth part of the thesis, we wanted to test the role of the allelic variants 
that have associated with bipolar disorder in recent genome-wide association 
studies (GWAS). We could confirm findings for the DFNB31, SORCS2, SCL39A3, 
and DGKH genes. The best signal in this study comes from DFNB31, which 
remained significant after multiple testing corrections. Two variants of SORCS2 
were allelic replications and presented the same signal as the haplotype analysis. 
However, no association was detected with the PALB2 gene, which was the most 
significantly associated region in the previous GWAS. 
Our results indicate that BP is heterogeneous and its genetic background 
may accordingly vary in different populations. In order to fully understand 
the allelic heterogeneity that underlies common diseases such as BP, complete 
genome sequencing for many individuals with and without the disease is required. 
Identification of the specific risk variants will help us better understand the 
pathophysiology underlying BP and will lead to the development of treatments with 
specific biochemical targets. In addition, it will further facilitate the identification 
of environmental factors that alter risk, which will potentially provide improved 
occupational, social and psychological advice for individuals with high risk of BP.
Keywords: Bipolar disorder, complex disease, linkage analysis, association analysis, 
cognition 
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Abstract in Finnish
Outi M. Palo. Genetic Background of Bipolar Disorder and Related Cognitive 
Impairments [Kaksisuuntaisen mielialahäiriön geneettinen tausta ja siihen liittyvät 
kognitiiviset häiriöt]. Terveyden ja hyvinvoinninlaitos (THL), Tutkimus 29, 140 
sivua. Helsinki 2010. 
ISBN 978-952-245-243-6 (painettu), ISBN 978-952-245-244-3 (pdf)
Kaksisuuntainen mielialahäiriö (BP) on monitekijäinen psykiatrinen sairaus, jol-
le on tyypillistä maanisten ja depressiivisten jaksojen toistuva vaihtelu. Kaksisuun-
taiseen mielialahäiriöön sairastuu noin 1 % koko maailman väestöstä ja sairautta 
esiintyy yhtälailla miehillä kuin naisilla. Kaksisuuntaisen mielialahäiriön puhkea-
miseen vaikuttavat geneettiset tekijät yhdessä kehitys- ja ympäristötekijöiden kans-
sa ja useat geenit todennäköisesti altistavat sairastumisriskiin. Kaksisuuntaiseen 
mielialahäiriön geenitaustan tunnemme kuitenkin vielä huonosti, vaikka inten-
siivisen ja pitkäaikaisen tutkimuksen avulla olemme tunnistaneet useita kromo-
somaalisia alueita ja geenejä, joiden arvellaan vaikuttavan kaksisuuntaiseen mieli-
alahäiriön alttiuteen. 
Tässä väitöskirjatutkimuksessa on pyritty paikantamaan geenivariantteja, jot-
ka altistavat kaksisuuntaiseen mielialahäiriöön suomalaisessa väestössä kandi-
geenianalyysin ja genomin laajuisen kytkentäanalyysin avulla. Diagnostisen luoki-
tuksen lisäksi analysoimme suoriutumista neuropsykologisissa testeissä ja näiden 
piirteiden mahdollista assosioitumista geenivariantteihin. Neuropsykologiset testit 
mittaavat kognitiivisia ominaisuuksia, jotka mahdollisesti liittyvät sairauteen, mut-
ta ovat sen puhkeamisesta riippumattomia piirteitä eli endofenotyyppejä. 
Väitöskirjan ensimmäisessä osassa tavoitteena oli tutkia TSNAX/DISC1 gee-
nialueen varianttien merkitystä psykoottisen ja bipolaarispektrin sairauksille. Eri-
laisilla alleelisilla haplotyypeillä havaitsimme olevan vaikutus näihin molempiin 
sairauksiin. DISC1 geenin 5’-päässä olevan haplotyypin todettiin periytyneen psy-
koosiin sairastuneille miehille (p = 0.008; laajennetulle haplotyypille, p = 0.0007 
molemmille sukupuolille), kun taas DISC1 geenin 3’-päässä olevan haplotyypin 
todettiin assosioituvan bipolaarispektrin sairauteen (p = 0.0002 laajennetulle hap-
lotyypille, p = 0.0001). Lisäksi haplotyypin variantit osoittautuivat assosioituvan 
useisiin kognitiivisiin piirteisiin. DISC1 geenin 5’-päässä olevan haplotyypin todet-
tiin assosioituvan useisiin kognitiivisiin piirteisiin, kuten toistovirheisiin ja kuu-
lonvaraiseen tarkkaavaisuuteen. Kun taas 3’ päässä olevat variantit assosioituivat 
kielelliseen sujuvuuteen ja psykomotoriseen prosessointinopeuteen.
Geenit, jotka liittyvät kolmeen täysin erilaiseen signallointisysteemiin, joiden 
tehtävänä on säädellä monia keskushermoston tehtäviä, on osoitettu altistavan kak-
sisuuntaiselle mielialahäiriölle. Tässä tutkimuksessa tutkimme kuutta funktionaa-
lista kaksisuuntaiseen mielialahäiriön kandigeeniä; serotoniiniin liittyviä geenejä 
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(SLC6A4 and TPH2), BDNF:n liittyviä geenejä sekä yhtä tulehdus ja sytokiniini-
systeemiin liittyvää geeniä (P2RX7) 723 suomalaisella bipolaariperheen-jäsenel-
lä. BDNF:n funktionaalinen variantti Val66Met assosioitui kaksisuuntaiseen mie-
lialahäiriöön ja parempaan suoriutumiseen muistiaineksen mielessä säilymisessä. 
Myös SLC6A4 geenin 5’–päässä olevien varianttien assosiaation pystyimme toista-
maan erityisesti miehillä (p = 0.004), mutta assosiaatiota laajasti tutkituille funk-
tionaalisille varianteille emme havainneet. Suojaava neljän variantin haplotyyppi 
geenissä P2RX7 assosioitui kaksisuuntaiseen mielialahäiriöön sekä toiminnan oh-
jaukseen, erityisesti foneemisessa (p = 0.0003) ja semanttisessa (p = 0.006) sana-
sujuvuudessa.
Väitöskirjan kolmannessa osatyössä tutkittiin 23 bipolaariperhettä, jotka ovat 
kotoisin Suomen koillisosasta. 6K varianttia testattiin genominlaajuisella kytken-
täanalyysillä. Merkittävimmät kytkentälöydökset havaitsimme kromosomialueella 
7q31 (LOD = 3.20) ja 9p13.1 (LOD = 4.02) havaittiin kromosomialueella 7q31. Jat-
kotutkimuksena analysoimme molemmat kytkentälöydökset parhaimmilla mark-
kereilla 179 perheellä. Kromosomialueen 9p13 kytkentälöydöksen pystyimme tois-
tamaan tässä aineistossa LOD-arvolla 3.02.
Väitöskirjan viimeisessä osatyössä testattiin genominlaajuisissa assosiaatio-
tutkimuksissa löydettyjen alleelisten varianttien assosioitumista kaksisuuntaiseen 
mielialahäiriöön. Pystyimme toistamaan löydökset DFNB31, SORCS2, SCL39A3, 
ja DGKH geeneille. Merkittävin tulos tuli geenistä DFNB31, mikä säilyi merkit-
tävänä myös moninkertaisen testauksen korjaamisen jälkeen. SORCS2-geenin va-
rianteista kaksi olivat alleelisia replikaatioita, jota tuki myös haplotyyppianalyy-
si. Aiemmissa koko genominlaajuisissa assosiaatioanalyyseissä merkittävimmän 
tuloksen antaneelle PALB2 geenille emme löytäneet näyttöä sen osuudesta kaksi-
suuntaiseen mielialahäiriöön suomalaisessa väestössä.
Tämän väitöskirjatyön tulokset ovat osoittaneet kaksisuuntaiseen mieliala-
häiriön olevan heterogeeninen ja sen geneettisen taustan vaihtelevan eri väestöjen 
välillä. Jotta voimme täysin ymmärtää kompleksitautien, kuten kaksisuuntaiseen 
mielialahäiriöön, taustalla olevien geneettisten tekijöiden alleelista heterogee-
nisyyttä edellytetään usean terveen ja sairastuneen henkilön koko genomin sek-
vensointia. Tiettyjen alttiusgeenien löytäminen auttaisi ymmärtämään kaksisuun-
taiseen mielialahäiriön tautimekanismia ja näin ollen mahdollistaisi paremmin 
tehoavien lääkkeiden kehittämistä. Lisäksi tällöin olisi myös mahdollista tunnistaa 
ympäristötekijöitä, jotka vaikuttavat alttiuteen sairastua. Perintö- ja ympäristöteki-
jöiden tunnistaminen auttaisi myös järjestämään asianmukaista ammatillista, sosi-
aalista ja psykologista tukea henkilöille, joilla on korkea riski sairastua kaksisuun-
taiseen mielialahäiriöön.
Avainsanat: kaksisuuntainen mielialahäiriö, monitekijäinen tauti, kytkentäanalyysi, 
assosiaatioanalyysi, kognitio
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Abbreviations
ADHD  Attention –deficit/hyperactivity disorder  
ALDH1B1 Aldehyde dehydrogenase 1B1 precursor 
ANK3 Ankyrin G
ARNTL Aryl hydrocargon receptor nuclear translocator-like gene
BP Base pair
BP Bipolar disorder
BP-I Bipolar disorder, type 1
BP-II Bipolar disorder, type 2
BP-NOS Bipolar disorder, not otherwise specified
BDNF Brain-derived neurotrophic factor
CACNA1C  Alpha 1C subunit of the L-type voltage-gated calcium channel 
CADPS2 Calcium-dependent activator protein for secretion 2 
Caspr3 Contactin-associated protein 3 
CLOCK Circadian locomotor output cycles kaput
cM Centimorgan
CNTNAP3 Contacting associating protein-like 3 
CNV Copy number variants 
COMT  Catechol-O-methyltransferase
COWAT The Controlled Oral Word Association Test 
CREB1 cAMP responsive element binding protein 1
CD-CV Common disease-common variant 
CVLT Californian Verbal Learning Test
DAOA  D-amino acid oxidase activator or G72 /G30
DFNB31 CASK-interacting protein CIP98 isoform 1
DGKH Diacylglycerol kinase, eta
DISC1 The Disrupted-in-Schizophrenia-1 gene
DNA  Deoxyribonucleic acid 
DSM-III-R  The Diagnostic and Statistical Manual of Mental Disorders, 
 revised third edition 
DSM-IV Diagnostic and Statistical Manual of Mental Disorders, fourth 
 edition
DPY19L3 Dpy-19-like 3
DZ Dizygotic
DISC1 Disrupted-in-Schizophrenia 1
EDTA Ethylenediaminetetraacetic acid
EGFR Epidermal growth factor receptor
FBAT Family–based association test 
GSK3-β  glycogen synthase kinase 3-β gene
GWAS Genome-wide association studies
HBAT  The haplotype extension of the FBAT program
hME Homogenous Mass Extension
HGP  Human Genome Project
HRR Haplotype relative risk
ICD-8 The International Classification of Diseases, version 8 
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ICD-10 The International Classification of Diseases, tenth revision
KCND2 Potassium-voltage-gated channel, member 2 
Kb Kilobase
LD Linkage disequilibrium
LOD Logarithm of odds
MAOA Monoamine oxidase A 
Mb Megabase
mRNA  Messenger RNA 
MYO5B Myosin 5B
MZ Monozygotic
NAP5 Nck-associated protein 5
NPL Non-parametric linkage 
NT-3 Neurotrophin-3 
NTRK2 Neurotrophic tyrosine kinase, receptor type 2
OR Odds ratio
PALB2 Partner and localizer of BRCA2
PCR Polymerase chain reaction
PER3 Period homolog 3
PLA2A Phospholipase A2 
PLAP  Phospholipase A2-activating protein 
P2RX7 Purinergic receptor ligand-gated ion-channel 7
QTDT Quantitive Transmission Disequilibrium test 
rMDD Recurrent major depression disorder
RNA Ribonucleic acid 
SA Schizoaffective disorder
SAD Seasonal affective disorder 
SCID Structured clinical interview 
SCZ Schizophrenia
SLC6A4 Solute carrier family 6 member 4
SLC39A3 Solute carrier family 39
SNP Single nucleotide polymorphism
SORCS2 Sortilin-related VPS10 domain containing receptor 2
STR Short tandem repeat
TDT Transmission disequilibrium test 
θ Theta, recombination fraction
TPH2 Tryptophan hydroxylase 2
TSNAX Translin-Associated factor X
TSPAN8  Tetraspanin-8 
UPD Unipolar disorder
WAIS-R  The Wechsler Adult Intelligence Scale-Revised 
WHO World Health Organization
WMS-R  The Wechsler Memory Scale-Revised
WTCCC The Wellcome Trust Case Control Consortium
Z Lod score
Gene names have been italicized in the text.
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1	 Introduction
Bipolar disorder (BP) is a severe mental disorder affecting approximately 1% 
of the world population. The disease is characterized by episodes of mania and 
depression. The episodes of depression are usually more frequent than the manic 
episodes, although the nature of the illness varies (Goodwin and Jamison 2007). 
The aetiology of BP is complex, but family, twin and adoption studies have 
demonstrated considerably high heritability of the disorder (Berrettini 2000a; 
Berrettini 2000b). The highest estimate, 93 %, is  based on the analysis of a Finnish 
twin study (Kieseppa et al. 2004), suggesting genetic factors play a strong role in 
BP pathogenesis in Finland. However, the importance of environmental effects are 
inferred from the relatively high discordance rate in monozygotic twins (Goodwin 
and Jamison 2007).
BP is recognized as a complex disease that is thought to be to the result of 
the collective involvement of several genes and the environment. The number and 
small effects of the predisposing genes makes identifying them challenging. 
Strategies for elucidating the specific genetic basis for BP include linkage and 
associating methods. Two alternative approaches have been commonly employed 
to identify in BP and other complex disorders. The functional candidate approach 
is based on the selection of genes that are thought to be involved in the biological 
processes of the disease. The positional candidate approach, on the other hand, is 
based on the selection of genes that are located in regions linked or associated to 
BP in linkage studies and genome-wide association studies. 
Using genetically isolated populations in studies of complex diseases can 
provide a great advantage in the identification of genetic factors contributing 
to risk of the disorder. The sequence of the human genome is largely known, 
enabling the identification and characterization of all associated genes. Increased 
information on molecular markers, improved genotyping technologies and efficient 
use of bioinformatic tools to analyze the genomic information enable us to better 
understand the genetic background of complex diseases. 
This study aims to investigate the genetic basis of bipolar disorder and to 
identify susceptibility genes for BP in Finnish families.
16 Research 29/2010
National Institute for Health and Welfare
Genetic Background of Bipolar Disorder and
Related Cognitive Impairments
2	 Review	of	literature
2.1 Genetic epidemiology of complex diseases
2.1.1 Genome and its variation
James Watson and Francis Crick discovered the structure of deoxyribonucleic 
acid (DNA) 56 years ago (Watson and Crick 1953) and the variation in the DNA 
sequences of genomes was recognized at the end of the 1970’s (Botstein et al. 
1980). The sequencing of the complete human genome and the localization of 
approximately 20 000 protein coding genes by The Human Genome Project (HGP) 
was achieved at the beginning of this century (Clamp et al. 2007; International 
Human Genome Sequencing Consortium 2000; Venter et al. 2001).
The human cell contains mitochondrial and nuclear genomes. The nuclear 
genome consists of roughly 3.2 billion base pairs (bp) of double stranded DNA that 
is organized and packed into 22 autosomal chromosomes and sex-determining X 
and Y-chromosomes. Each individual receives one chromosome of each type from 
each parent, with the end result of having 22 autosomal chromosomes and a sex 
chromosome pair of either XX in females or XY in males. The genomic sequences 
of the protein-coding genes contain protein-coding exons, introns, promoters 
and other regulatory regions. In addition, the genomic sequence contains non-
coding information that is not translated into a protein, but is used as functional 
elements, such as ribonucleic acid (RNA) molecules, and so-called “junk DNA” 
whose function is still poorly known (Gerstein et al. 2007) (Figure 1).
Among humans the genome is approximately 99.5 % identical. Any given 
individual differs genetically 0.1-0.5 % from other humans, which is caused by 
several types of sequence variation and polymorphisms (Levy et al. 2007). The 
genetic variation in humans arises from: (1) mutation, including point mutations 
caused by substitution, deletion or insertion; (2) chromosomal rearrangements, 
including deletion, duplication, inversion, insertion and translocation; and (3) 
random assortment of the chromosomes into gametes (Figure 2). Mutations can be 
silent, alter gene expression or change protein production leading occasionally to 
changes in phenotypes. If mutations occur in the germ line, they are transmitted to 
offspring and create variation in the population.
2   Review of literature
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FIGURE 1. The structure of the human genome. The genome is over three billion base pairs 
of double stranded DNA that is wrapped around histone proteins and tightly packed into 
23 chromosome pairs in the nucleus of the cell. The human genome contains an estimated 
20,000 protein-coding genes as well as non-coding genes, regulatory sequences, introns 
and “junk” DNA (http://www.genome.gov/glossary.cfm). 
2   Review of literature
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FIGURE 2. The main types of the mutation in the genome. 
Short tandem repeats (STRs) or microsatellites have traditionally been the 
most utilized markers for genome-wide scans (Figure 3). Microsatellites are short 
di-, tri-, or tetranucleotide tandem repeat sequencesthat are highly polymorphic 
among individuals (Weber and May 1989). There are over 300  000 known 
microsatellites in the human genome (NCBI Build 36.2).
Single nucleotide polymorphisms (SNPs) are bi-allelic markers, which are 
densely spread throughout the human genome, occuring approximately once in 
every 300 BP (Kruglyak and Nickerson 2001). At present, almost seven million 
SNPs have been identified and validated (NCBI Build 36.2). Since our knowledge 
of the human genome sequence is based on only a few sequenced individuals, the 
number of SNPs is likely underestimated and current estimates exceed 14 million 
(Kruglyak and Nickerson 2001; Levy et al. 2007). SNPs are conventionally utilized 
for fine mapping in the positional candidate gene and functional candidate gene 
approaches. Sets of hundreds of thousands of SNPs on a single array chip have 
been recently used for screening the whole human genome (Carlson et al. 2004; 
Hirschhorn and Daly 2005).
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FIGURE 3. The main types of genetic variants utilized in genetic mapping. 
Another type of human genome variation is copy number variants (CNVs), 
which are large genomic regions ranging from a few kilobases (kb) to several 
megabases (Mb) long that vary in copy number between individuals. CNVs are 
common and they have been estimated to cover 12 % of the human genome (Redon 
et al. 2006). CNVs have been shown to influence gene expression and gene dosage 
being the important structural basis for genetic recombination of the genome. 
2.1.2 Strategies to identify genes underlying complex   
 traits
The role of genetic factors in the etiology of diseases varies greatly; some diseases 
are determined mainly by genes, while others are induced by environment or 
by gene-environment interactions. Genetic disorders that are caused by highly 
penetrant mutations in a single gene are called monogenic disorders or Mendelian 
disorders. Monogenic disorders display clearly identifiable patterns of inheritance 
(dominant, recessive or X-linked inheritance) and they are usually rare, such as 
those in the Finnish disease heritage (Norio 2003). Most of the genes responsible 
for monogenic disorders have been successfully identified by linkage analysis 
and positional cloning. However, for many complex disorders the identification 
of predisposing genes has been more challenging (Table 1). Complex disorders 
are caused by numerous genes interacting with each other and environmental 
risk factors. Complex disorders, such as bipolar disorder, depression, diabetes, 
cardiovascular diseases and asthma, affect more people globally than monogenic 
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disorders. Complex diseases display a complex pattern of inheritance with late 
onset and incomplete penetrance, and thus they are more likely to be caused by 
several genes.
Hypotheses of the manner by which allelic variants cause complex diseases 
differ. The most well-known hypothesis, the common disease-common variant 
(CD-CV) hypothesis, suggests that common diseases may be caused by a large 
number of genetic variants with a relatively high frequency in the population 
(Collins et al. 1997; Lander et al. 2001). The alternative hypothesis, the heterogeneity 
model, argues that common diseases are caused by several rare variants with strong 
phenotypic effects (Wang et al. 2005). According to the neutral selection hypothesis, 
common variants would have low contribution to the genetic variation since they 
would be close to the fixation in the constant size population (Pritchard 2001; Wang 
and et al.2005). Currently we do not have enough evidence to determine which of 
these hypotheses best describes the nature of allelic variants underlying complex 
diseases. The reality probably lies between these hypotheses with both rare and 
common variants contributing to susceptibility to complex disorders. 
TABLE 1. Complicating factors in the identification of genes predisposing to complex 
disorders.
Genetic factors Unknown mode of inheritance
Unknown allele frequency
Epistasis
Genetic heterogeneity
Gene-environment interaction
Phenotypes Difficulties in diagnosis
Late onset of the disease
Pleiotrophy
Phenocopies
Incomplete penetrance
Technical issues Affordable large-scale genotyping methods
Completeness of genetic data in public databases
Statistical analyses Multiple testing
Limited statistical power
Publication bias A tendency to publish significant results, but not negative or 
neutral results
One strategy to identify susceptibility genes underlying complex disorders is 
linkage analysis, which aims to identify chromosomal regions linked to disease 
by following the co-segregation of markers and traits in families. In other words, 
linkage analysis assesses the linkage probability of two loci on a chromosome by 
using the frequency of meiotic recombination as an estimate of genetic distance. 
The recombination fraction, theta (θ), ranges from θ = 0 for loci right next to each 
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other to θ = 0.5 for loci far apart. A theta θ < 0.5 is observed when two loci co-
segregate, and are thus genetically linked. The aim of linkage analysis is to test 
whether an observed deviation from 50 % recombination between two loci is 
statistically significant. The statistical significance is measured using a logarithm 
of odds (LOD) score. LOD scores greater than or equal to 3 are considered to show 
statistically significant linkage (Ott 1999; Ott and Bhat 1999; Terwilliger and Ott 
1993). After genome-wide linkage scans, the identified chromosomal loci are fine 
mapped by a denser set of markers in order to narrow down the region and identify 
causative variants. 
Association analysis aims to identify alleles that differ systematically 
between affected and non-affected individuals. This strategy is likely to be more 
powerful than linkage studies in identifying susceptibility genes with small effects. 
Association studies can be used in different types of study samples, including case-
control samples. Case-control studies are prone to false positive associations caused 
by population stratification and systematic errors in control sampling. Population 
stratification refers to the genetically different subgroups in samples that can cause 
cases and controls to be match poorly genetically. Relatively large sample sizes are 
required to detect susceptibility variants with only small effects. 
In family-based association studies, the Haplotype-relative risk (HRR) 
method is one method used to compare the frequencies of genotypes and alleles 
between proband and control groups, the latter being composed of alleles not 
transmitted to affected individuals. Parental alleles are sorted into transmitted 
alleles to affected offspring and non-transmitted alleles (Falk and Rubinstein 1987; 
Ott 1999). A modification of HRR is the transmission disequilibrium test (TDT), 
which uses data from parents and their affected offspring to test linkage in the 
presence of linkage disequilibrium (LD). The frequency of transmitted alleles and 
non-transmitted alleles of parental controls are compared (Spielman and Ewens 
1996; Spielman et al. 1993; Spielman et al. 1994). The main disadvantage of the 
family-based association studies is that parental data is not always available. 
The LD method measures if the co-occurrence of two variants at different 
loci differs from chance occurrence (Kruglyak 1999). The most commonly used 
measures for LD are D’ and r2, which are scaled such that 0 signifies no LD and 
1 to total LD (ie. no recombination). Both measures are independent of allele 
frequencies and can be used to compare differences in LD between loci (Ardlie 
et al. 2002; Weiss and Clark 2002). LD results from the inheritence of a particular 
marker and disease susceptibility allele together as a unit, or haplotype, which over 
time and after several generations can still be detected (Terwilliger and Goring 
2000). As a result, the susceptibility allele will be detected in affected individuals 
in numerous apparently unrelated individuals and families. Therefore, even when 
the association of the susceptibility allele is not tested, the other alleles that are in 
LD with susceptibility allele will be inherited together in the same haplotype more 
often than expected by chance. Recombinations in the genome do not occur evenly. 
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Instead, they occur more frequently in recombination hotspots, resulting in block-
like structures across the genome. These haploblocks consist of regions with low 
recombination rates, and thus variants within a block are in considerable LD. For 
this reason, a few SNPs can be selected for genotyping to obtain information on 
the adjacent SNPs within these haploblocks. Only these “tagging” SNPs need to be 
genotyped in order to describe the genetic variation of haploblocks (Hirschhorn 
and Daly 2005). Although a majority of haplotypes is shared between populations, 
there are still some parts of the genome that cannot be tagged and individual SNPs 
need to be genotyped Frazer et al. 2007). The size of LD varies across populations. 
Due to the population history of Finland, the genome of Finns appears to have 
increase in LD compared to other populations, which facilitates the gene mapping 
of complex diseases in the Finnish population (Peltonen et al. 1999; Varilo and 
Peltonen 2004). The most significant value of isolated populations is the lower 
genetic variability that results in the enrichment of a subset of predisposing 
alleles. Enrichment of predisposing alleles will require fewer individuals for the 
mapping of genes involved in the etiology of the complex disorders. In addition, 
isolated populations, such as Finns and Sardinians, have similar LD levels to other 
populations in Europe and the United States (Kaessmann et al. 2002).
The HapMap project was undertaken to catalogue all the common variants 
with minor allele frequencies of at least 1–5 % in a SNP and haplotype map of the 
human genome. It was meant to accelerate the discovery of the susceptibility genes 
underlying common andcomplex diseases (The International HapMap Consortium 
2003). Most of the panels used in genome-wide association studies (GWAS) are 
based on the HapMap data, and therefore it is worth noting that they are designed 
to detect common variants and may not detect rare genetic variants(Hirschhorn 
and Daly 2005). The recent GWAS use dense mapping methods covering the 
genome with 300K-1M SNPs and have large case-control study samples of several 
thousands of individuals (McCarthy et al. 2008). GWAS have identified common 
variants showing association with common complex diseases, such as type 2 
diabetes (Saxena et al. 2007), Crohn’s disease (Rioux et al. 2007) and prostate cancer 
(Gudmundsson et al. 2007). Replication has become the gold standard for assessing 
results from GWAS. However, the replication requirement may cause real genetic 
effects to be missed. A real result can fail to replicate for numerous reasons, such as 
inadequate sample size or variability in phenotype definitions across independent 
samples. Failure to replicate may provide important clues about the complexity 
of the underlying genetic architecture of the disease and non-replicated variants 
could be checked for interactions with other variants, particularly when samples 
are collected from different populations (Greene et al. 2009).The use of haplotype-
based association tests and the imputation of missing data can improve the power 
of GWAS. In the context of GWAS, there are several applications of missing 
data imputation. By means of a reference panel, imputation can be used to infer 
genotypes for ungenotyped known variants, to fill in the genotypes that have failed 
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to pass quality control standars, to combine results from many studies that have 
used different sets of variants and in family-based GWAS to infer the genotypes 
of unavailable family members (Dudbridge 2008). In addition, meta-analysis of 
multiple and smaller GWAS can provide adequate power to detect common variants 
with modest relative risk. Furthermore, the susceptibility variants reported from 
GWAS meta-analyses can be tested with smaller study samples. However, it should 
be noted that meta-analysis are only beneficial if the underlying genetic risk factors 
can be assumed to be shared across the different study populations used. 
2.1.3 The Finnish population and its subisolates
Finland mainly became inhabited by two immigration waves: the first occurring 
about 4000 years ago coming from the East, and the second 2000 years ago from 
the South (Kittles et al. 1998). In the 1500’s internal migrations caused a population 
explosion and small isolated villages were established by only a few founders 
throughout the wilderness (Figure 4) (Varilo and Peltonen 2004). The founding 
population of Finland was very small and has experienced multiple bottlenecks. 
Famines, wars and infectious diseases reduced the population size temporarily, 
caused losses of genetic variation and were followed by subsequent rapid expansions 
FIGURE 4. The settlement waves of Finland. Early habitation of Finland followed the 
coastline (Early Settlement). In the 16th century the internal migration movement originated 
from Southern Savo (shaded gray) to the central and eastern parts of Finland, resulting in 
genetically isolated subpopulations that were established by only a few founders and were 
isolated by distance from each other (Late settlement). Picture modified from Varilo et al 
2003. Reproduced with permission of the copyright holder.
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of the population size characterized by relative inbreeding and isolation, which has 
reduced further allelic diversity (Nevanlinna 1972; Norio 1966; Varilo and Peltonen 
2004). Due to geographical, cultural and language barriers, the Finnish population 
has remained isolated from eastern and western neighbouring countries.
On the basis of Finnish population history and the special set of recessive 
diseases found in Finland, the Finnish population has been considered an isolated 
population (de la Chapelle 1993; Nevanlinna 1972; Norio et al. 1973; Varilo and 
Peltonen 2004). The Finnish genome shows decreased genetic diversity and 
increased LD compared to other populations in Europe and particularly in Africa 
(Lander and Schork 1994; Peltonen 2000). Accordingly, positional cloning has 
been most successful in indentifying the genetic variants of several rare monogenic 
disorders in Finland (Aittomaki et al. 1995; Cremers et al. 1990; Hastbacka et al. 
1994; Kestilä et al. 1998; Peltonen et al. 1995; Savukoski et al. 1998) and it may be 
further advantageous in the identification of genetic variants in complex diseases 
(Service et al. 2006).
Due to the population history of Finland, the prevalences of several traits 
vary between subisolates and individuals categorized by the birthplaces of their 
grandparents show genetic clustering by region. A population substructure and 
geographically uneven distribution of disease alleles can be still detected (Jakkula et 
al. 2008; Salmela et al. 2006) (Figure 5). A subisolate population can be valuable for 
Figure 5. The subisolate population structure within Finland. Data of samples from ten 
distinct Finnish early- and late-settlement subisolates are shown with multidimensional 
scaling. The colored dots indicate samples from the corresponding colored regions of the 
Finland. Modified from Jakkula et al. 2008. Reproduced with permission of the copyright 
holder.
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the genetic mapping and identification of rare penetrant risk variants. However, the 
use of isolates can lead to false positive association due to population stratification 
if the cases and controls originate from genetically distinct subpopulations having 
distinct allele frequencies (Hirschhorn and Daly 2005). In order to avoid population 
stratification, study samples should be selected carefully or family-based study 
samples should be used. 
2.2 Bipolar disorder
2.2.1 Diagnosis
BP or manic-depressive illness is characterized by episodes of depression, mania, 
hypomania or mixed states and euthymia. Other psychiatric symptoms, such as 
delusions and hallucinations may occur during episodes (Goodwin and Jamison 
2007). BP has a lifetime pattern of, at least, one manic or hypomanic episode with 
depressive episodes. Hypomania is differentiated from mania by the lower degree 
of impairment in function, and the disturbances of mood and behaviour are not 
accompanied by hallucinations and delusions (WHO 1993). One episode lasts 
from one week to several months. BP may start with depression and it can take 
many depressive episodes before the first mania episode occurs (Akiskal 2005). The 
depressive episodes are usually more frequent than the manic episodes, although 
the course of illness varies among individuals (Goodwin and Jamison 2007). BP 
is typically recurrent. The age of onset is usually in late adolescence, around 20 
years of age and over 90 % of the patients experience their first manic episode 
before the age of 35 (Rihmer and Angst 2005). There is an elevated tendency for co-
morbidity with drug abuse, alcoholism, compulsive behaviour, attention-deficit/
hyperactivity disorder (ADHD) and anxiety (Krishnan 2005; Mantere et al. 2006). 
Bipolar disorder is associated with high levels of morbidity and mortality with up 
to 15 % of patients eventually committing suicide (Goodwin and Jamison 2007). 
The diagnosis of BP is based on the evaluation of signs and symptoms as 
described in established diagnostic criteria. The current diagnostic criteria are 
presented in the International Classification of Diseases, tenth revision (ICD-10) 
(WHO 1993) and the Diagnostic and Statistical Manual of Mental Disorders of 
the American Psychiatric Association, fourth revision (DSM-IV). BP is divided 
into bipolar disorder type I (BP-I), type II (BP-II) and not otherwise specified (BP-
NOS) (Table 2–5). 
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TABLE 2. DSM-IV criteria for Manic Episode.
A. A distinct period of abnormally and persistently elevated, expansive or irritable 
mood, lasting at least one week (or less if hospitalization is required).
B. During the period of mood disturbance, three (or more) of the following symptoms 
have persisted (four, if the mood is only irritable) and have been present to a 
significant degree:
1. inflated self-esteem or grandiosity
2. decreased need for sleep
3. more talkative than usual or pressure to keep talking
4. flights of ideas or subjective expereince that thoughts are racing
5. distractibility (i.e.attention too easily drawn to unimportant or irrelevant external 
    stimulus)
6. increased involvement in goal-directed activities or psychomotor agitation
7. excessive involvement in pleasurable activities with a high potential for painful 
    consequences.
C. The symptoms do not meet criteria for a Mixed Episode.
D. The mood disturbance is sufficiently severe to cause marked impairment in 
occupational functioning or in usual social activities or relationships with others or 
to necessitate hospitalisatio to prevent harm to self or others or there are psychotic 
features.
E. The symptoms are not due to the direct physiological effects of a substance (e.g. 
drug  of abuse, a medication or other treatment) or a general medical condition.
Diagnosis of bipolar disorder according to the Diagnostic and statistical manual of mental disorders, 
Fourth Edition (DSM-IV), Text Revision (American Psychiatric Association 2000).
TABLE 3. DSM-IV criteria for Hypomanic Episode.
A. A distinct period of persistently elevated, expansive or irritable mood, lasting 
throughout at least four days that is clearly different from the usual nondepressed 
mood.
B. During the period of mood disturbance, three (or more) of the following symptoms 
have persisted (four, if the mood is only irritable) and have been present to a 
significant degree:
1. inflated self-esteem or grandiosity
2. decreased need for sleep
3. more talkative than usual or pressure to keep talking
4. flights of ideas or subjective expereince that thoughts are racing
5. distractibility (i.e.attention too easily drawn to unimportant or irrelevant external 
    stimulus)
6. increased involvement in goal-directed activities or psychomotor agitation
7. excessive involvement in pleasurable activities with a high potential for painful 
    consequences.
C.  The episode is associated with an unequivocal change in functioning that is 
uncharacteristic of the person when not symptomatic.
D. The disturbance in mood and the change in functioning are observable by others. 
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E. The episode is not severe enough to cause marked impairment in social or 
occupational functioning or to necessitate hospitalisation and there are no psychotic 
features.
F. The symptoms are not due to the direct physiological effects of a substance (e.g. 
drug of abuse, a medication or other treatment) or a general medical condition.
Diagnosis of bipolar disorder according to the Diagnostic and statistical manual of mental disorders, 
Fourth Edition (DSM-IV), Text Revision (American Psychiatric Association 2000).
TABLE 4. DSM-IV criteria for Major Depressive Episode.
A. Five (or more) of the following symptoms have been present during the same two 
week period and represent a change from previous functioning; at least one of the 
symptoms is either depressed mood or loss of interest or pleasure:
1. depressed mood most of the day, nearly every day
2. markedly diminshed interest or pleasure, in all, or almost all, activies most of the 
    day, nearly every day
3. significant weight loss or gain or decrease, or increase inappetite nearly every day
4. insomnia or hypersomnia nearly every day
5. psychomotor agitation or retardation nearly every day (observable by others)
6. fatigue or loss of energy nearly every day
7. feelings of worthless or excessive or inappropriate guilt nearly every day
8. diminshed ability to think or concentrate, or indecisiveness, nearly every day
9. recurrent thoughts of death, recurrent suicidal ideation without specific plan or a 
    suicide attempt or a specific plan for committing suicide
B. The symptoms do not meet criteria for a Mixed Episode.
C. The symptoms cause clinically significant distress or impairment in social, occupational 
or other important areas of functioning.
D. The symptoms are not due to the direct physiological effects of a substance (e.g. 
drug of abuse, a medication or other treatment) or a general medical condition.
E. The symptoms are not better accounted for by bereavement.
Diagnosis of bipolar disorder according to the Diagnostic and statistical manual of mental disorders, 
Fourth Edition (DSM-IV), Text Revision (American Psychiatric Association 2000).
TABLE 5. DSM-IV criteria for Mixed Episode.
A. The criteria are met for both a manic Episode and for a Major Depressive Episode 
(except duration) nearly every day during at least a one week.
B. The mood disturbance is sufficiently severe to cause marked impairment in 
occupational functioning or in usual social activities or relationships with others or 
to necessitate hospitalisation to prevent harm to self or others or there are psychotic 
features.
C. The symptoms are not due to the direct physiological effects of a substance (e.g. 
drug of abuse, a medication or other treatment) or a general medical condition.
Diagnosis of bipolar disorder according to the Diagnostic and statistical manual of mental disorders, 
Fourth Edition (DSM-IV), Text Revision (American Psychiatric Association 2000).
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Bipolar disorder type I (BP-I) is characterized by the occurrence of one or 
more manic or mixed episodes and depressive episodes. The predominant mood of 
manic episodes is elevated or irritable, which is accompanied by increased energy 
and activity, inflated self-esteem with grandiose ideas, pressure to talk, decreased 
need for sleep, increased sexual activity and impulsive behaviour. Mania may 
include psychotic symptoms as well, such as delusions and hallucinations. The 
most severe forms of mania cause marked impairment in social or occupational 
functioning requiring hospitalization. Manic episodes have to last at least one week 
in order to be diagnosed as BP-I. The predominant mood of the depressive episodes 
is a depressed mood and loss of interest, which is accompanied by reduced self-
confidence, decreased energy and activity and feelings of guilt and worthlessness. 
The severe depression causes marked impairment in social or occupational 
functioning (American Psychiatric Association 1994; WHO 1993).
Bipolar disorder type II (BP-II) involves depressive and hypomanic episodes, 
but not manic episodes. Hypomanic episodes are a milder form of mania 
characterized by a persistent mild elevation of mood, increased energy, self-
esteem, sociability and sexual energy. Furthermore, irritability and decreased need 
for sleep may be present in hypomania. Psychotic symptoms do not accompany 
hypomania. Hypomania is not severe enough to cause marked impairment in social 
or occupational functioning and it does not require hospitalization (American 
Psychiatric Association 1994; WHO 1993)
Cyclothymia has features similar to manic episodes and major depressive 
episodes without marked impairment in social or occupational functioning during 
hypomanic episodes. It is characterized by numerous short periods of mood swings, 
which are milder than in BP-I or BP-II, separated by short periods of normal mood. 
Cyclothymia is a chronic condition that periods without hypomanic or depressive 
symptoms less than two months at a time (American Psychiatric Association 1994; 
WHO 1993).
Mixed episode is a period in which both manic and major depressive episodes 
are present nearly every day over at least one week. In addition, it can be characterized 
by the presence of psychotic features. Mixed episodes cause marked impairment in 
social or occupational functioning and it may require hospitalization (American 
Psychiatric Association 1994; WHO 1993). 
Rapid cycling mood is a period when manic and depressive moods change 
faster than is normal for the manic or major depressive phase (American Psychiatric 
Association 1994; WHO 1993).
Schizoaffective disorder (SA) shares features from both BP (mania and 
depression) and schizophrenia (SCZ) (hallucinations, delusions, disorganized 
speech, disorganized or catatonic behaviour and negative symptoms), thus falling 
in between SCZ and BP. SA can be specified as a bipolar type with concurrent or 
previous manic syndrome, or as a depressive type with the absence of current or 
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previous manic syndrome. All symptoms of BP and SCZ can appear together or 
independently (American Psychiatric Association 1994; WHO 1993).
Bipolar disorder, Not Otherwise Specified (NOS) is a diagnosis for those 
who show clear symptoms of BP, but do not meet the full diagnostic criteria. 
For example, hypomania without depression belongs to this group (American 
Psychiatric Association 1994; WHO 1993).
Seasonal affective disorder (SAD) is diagnose with a characteristic seasonal 
variation (American Psychiatric Association 1994; WHO 1993).
2.2.2 Epidemiology
Epidemiology is the study of the distributions of diseases in human populations 
and the variation of these distributions among different population subgroups. 
Prevalence is an epidemiological measure of the proportion of individuals that have 
a disorder at a specified time or during a specified period. Lifetime prevalence is the 
proportion of individuals in a population on a given day that have, at some point, 
been diagnosed for the disorder. As a result of differences in the methodologies and 
diagnostic classifications, measures of estimated lifetime prevalence of BP range 
from 0.1 to 4.8 % globally (Table 6) (Rihmer and Angst 2005). The World Health 
Organization (WHO) has assessed that BP is a marked global burden in society 
on par with SCZ in terms of premature deaths, leave of absence and poor health-
related quality of life (Vos and Mathers 2000).
The annual incidence varies from 3 to 10 persons per 100 000 in the general 
population (Rihmer and Angst 2005). In Finland, the incidence of first-time 
hospital admissions for BP in 1994was reported at 12 persons per 100 000 (Rasanen 
P 1998), in contrast to the incidence of a first-time hospital admission for mania 
in the northern part of Finland that was reported at 1.7 persons per 100 000 per 
year (Veijola et al. 1996). The most recent Finnish population studies are based on 
the Health 2000 Study. They have estimated the lifetime prevalence of bipolar I 
disorder at 0.24 % in persons 30 years and older (Perala et al. 2007), and in young 
Finnish adults aged 19 to 34 years the prevalence is estimated to be 0.53 % for 
bipolar I disorder, 0.72 % for bipolar II disorder and 0.61 % for bipolar disorder, 
not otherwise specified (Suvisaari et al. 2009)
Many studies have reported an association between BP and stressful life events, 
which may also lengthen recovery periods (Altman et al. 2006; Hillegers et al. 
2004). In addition, other mediating factors, such as personality traits, social support 
and sleep, may play role in increasing the risk of BP recurrence. Furthermore, 
pregnancy and childbirth may predispose to BP. It has been suggested that women 
have more than two–fold risk for BP after childbirth (Altman et al. 2006; Hillegers 
et al. 2004). Other predictors of bipolar episodes include: an increased number 
of previous episodes, decreased intervals between episodes, and persistence of 
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affective symptoms and episodes. However, evidence is still inconclusive and many 
aspects of the interaction between these factors and BP need to be considered in 
future studies (Tsuchiya et al. 2003). 
Family-, twin- and adoption studies can be used to make a distinction between 
genetic and environmental factors contributing to disease susceptibility. Family 
studies have shown that BP aggregates in families. The morbid risk of developing 
BP for first-degree relatives of bipolar patients ranges from 1.5 to 17.9 % with a 
weighted average of 7.8 % (McGuffin and Katz 1989). Similarly, Smoller and Finn 
reported a weighted average of 8.7 % morbid risk to relatives of BP-I or -II probands 
(Smoller and Finn 2003). Relatives of BP probands have elevated morbid risk for 
other psychiatric diagnoses, such as unipolar disorder, schizoaffective disorder, 
cyclothymic personality and suicide (McGuffin and Katz 1989). 
The difference between monozygotic (MZ) and dizygotic (DZ) concordance 
for a certain disorder indicates the genetic effect of the disorder. For complex traits, 
the MZ concordance is usually less than 100 % indicating that environmental 
factors contribute to disease risk. Twin studies have shown higher BP concordance 
in MZ twins than in DZ twins. Proband concordance rates have varied from 33 to 
75 % for MZ twins and from 0 to 13 % for DZ twins. The results suggest a strong 
genetic component to BP, although its strength estimate varies between studies. In 
Finnish twin studies, the proband concordance rates were 43 % for MZ twins and 6 
% for DZ twins, and heritability was estimated at 93 % (Kieseppa et al. 2004).
Adoption studies can determine the concordance risk for non-biological 
relatives of an affected individual and the proportional effects of genetic and 
environmental (post-natal) factors can be monitored. A study of 29 adoptees 
having BP reported more mood disorders among biological parents (31 %) than 
among adoptive parents (12 %) (Mendlewicz and Rainer 1977). However, the small 
number of study subjects and contradicting results limit the explanatory power 
of the adoption study results. It can be reasoned on the basis of these studies that 
the susceptibility to BP is largely genetic but environmental factors are needed to 
trigger the disorder, and thus BP is a result of a complex interaction between genes 
and environmental factors (Goodwin and Jamison 2007).
TABLE 6. Epidemiology of bipolar disorder.
Caucasian 
populationa
Finnish 
populationb
Recurrence risk in sibling of a proband (λs) 5–10 -
Probandwise MZ twin concordance (%) 36–80 43
Proband DZ twin concordance (%) 0–13 6
Heritability estimate (%) 79–99 93
a Estimates from Craddock and Forty 2006.
b Estimates from Kieseppä et al. 2004.
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2.2.3 Etiology and pathophysiology
Various abnormalities have been reported in BP patients, but little is known about 
the specific pathophysiology of bipolar disorder. The discovery of lithium’s efficacy 
as a mood-stabilizer has led investigators to examine the signal transduction 
pathways involved in bipolar disorder. Lithium is a simple monovalent cation 
actively transported by the sodium-potassium-ATP pump through the cell 
membrane. The precise mechanism of action of lithium as a mood stabilizing agent 
is still unknown, but it has been found to play a role in several second messenger 
systems, such as cAMP and phosphoinositol pathways, by inhibiting the enzyme 
inositol monophosphate, leading to high levels of inositol triphosphate (Einat 
et al. 1998). Lithium is used for in the acute manic phase and as prophylaxis for 
recurrent manic and depressive episodes (Machado-Vieira et al. 2009). However, 
increasing evidence suggests that a significant number of patients do not respond 
adequately or cannot tolerate lithium side effects. It is hoped that by understanding 
lithium’s therapeutic target, novel drugs with lithium-mimetic properties will be 
developed (Quiroz et al. 2004a; Quiroz et al. 2004b). Chronic administration of 
lithium and other mood stabilizers, such as carbamazepine, sodium valproate 
and lamotrigine, has been found to downregulate the arachidonic acid cascade in 
brain phospholipids, the formation of prostaglandin E(2), and/or the expression of 
arachidonic acid cascade enzymes that corresponds to the inhibition of arachidonic 
acid neurotransmission via dopaminergic- and glutamatergic N-methyl-D-
aspartate receptors (Rapoport et al. 2009; Shi et al. 2008b).
In addition to lithium, typical antipsychotic drugs, such as dopamine 
and serotonin antagonists, are useful in the treatment of acute mania and as a 
maintenance treatment. The continued effect of these drugs on the dopaminergic 
(Brugue and Vieta 2007; Dunlop and Nemeroff 2007; Gershon et al. 2007; Nutt 
2006), serotonergic and noradrenergic (Coppen 1969; Schildkraut 1965) systems 
has led to propositions of the roles of these systems in the aetiology of BP. 
Dopamine antagonists are not particularly selective and tend to block D2 receptors 
in the dopamine pathways of the brain. Blocking dopamine in the receptors of 
the mesolimbic pathway has been thought to control psychotic experiences. 
Current evidence of the deficiencies of monoamines 5-hydroxytryptamine (5-HT, 
serotonin) and norepinephrine in the pathophysiology of bipolar disorder includes 
brain images studies (Cannon et al. 2007; Zipursky 2007), transgenic mouse 
models (Lesch and Mossner 2006; Urani et al. 2005) genetic association studies 
(Craddock and Forty 2006; Craddock and Jones 2001a; Kato 2007; Levinson 2005), 
and gene expression studies (Elashoff et al. 2007; Higgs et al. 2006). However, not 
all studies have supported their role in BP (Craddock and Forty 2006; Hayden and 
Nurnberger 2006). 
Evidence for GABAergic and glutamatergic deficits in the pathophysiology 
and treatment of BP include neuroimaging, gene expression, gene association and 
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animal studies (Brambilla et al. 2003; Krystal et al. 2002; Kugaya and Sanacora 
2005; Paul and Skolnick 2003; Sanacora 2008). Other neurotransmission systems, 
such as the cholinergic system, may also be involved in the pathophysiology 
of BP (Belzung et al. 2006; Berton and Nestler 2006; Hauger et al. 2006; Young 
2006). Studies on the serotonergic systems of the CNS and the interaction among 
neurotransmitter receptors, G-proteins and signal transduction pathways, are 
required to better understand the pathology of BP.
There is robust evidence demonstrating the role of abnormalities of the 
hypothalamic-pituitary-adrenal axis in bipolar disorder. Abnormalities of various 
hormones and their regulatory systems, such as cortisol, thyroid-stimulating 
hormone and melatonin, may be central to the pathogenesis of BP (Takahashi et 
al. 2009). Hyperthyroidism has been associated with bipolar disorder, particularly 
with rapid cycling BP with predominant depressive episodes (Cassidy et al. 2002).
Technological improvements have made possible the study of the relationship 
between BP and neuropathology. Structural neuroimaging can be attained with 
tomography and magnetic resonance imaging (MRI), and functional information 
of the brain with functional MRI (fMRI). Studies of structural brain changes in BP 
have had highly variable reported findings and no consistent alterations have been 
found. Several studies have found abnormalities in the frontal lobe suggesting that 
the frontal lobe, limbic and basal ganglia circuits may play a role in the pathology of 
BP. MRI studies have reported an increased number of white matter hyperintensities 
in the frontal lobes, enlarged lateral ventricles, decreased overall brain grey matter 
volumes, the involvement of the temporal lobe; particularly hippocampus and 
amygdala, increased striatal size and decreased prefrontal cortex size (Davis et al. 
2004; Lopez-Larson et al. 2002; McDonald et al. 2004). fMRI studies have shown 
abnormalities in the regulation of prefrontal-subcortical circuits (Chang et al. 
2004), limbic-paralimbic blood flow and limbic metabolic alterations (Mayberg et 
al. 1999). These findings are also supported by magnetic resonance spectroscopy 
studies that implicate the presence of abnormal brain energy metabolism in BP 
(Dager et al. 2008).
Disruptions in biological rhythms have long been associated with BP (Jones 
2001; Mansour et al. 2005; McClung 2007; Wehr et al. 1983). Abnormal sleep-
wake, appetite and social rhythms are core symptoms of both manic and depressive 
episodes of BP. Sleep disturbance in BP has been hypothesized to be caused by 
abnormal circadian function, such as dysfunctional timing of sleep or the changed 
amount of sleep. Sleep disturbances may further trigger emotion dysregulation or 
vice versa (Dahl 2004; Harvey 2008; Harvey et al. 2006). In addition, severe social 
rhythm disruptions, such as moving, losing a job or returning from international 
trips, were found to be associated with onsets of mania in BP patients (Malkoff-
Schwartz et al. 1998; Malkoff-Schwartz et al. 2000). Some treatments for BP seem 
to affect circadian rhythms by shifting, resetting and stabilizating these rhythms 
(McClung 2007).
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Patients with BP present impaired cognitive performance compared to 
healthy individuals. Sustained attention, executive functioning, verbal learning and 
memory, verbal working memory and psychomotor speed are particularly impaired 
in bipolar patients in all phases of the disorder compared to healthy individuals 
(Glahn et al. 2004; Schneider et al. 2008). Impaired cognitive performance in 
verbal learning and memory, executive functions and attention may persist 
in remitted or euthymic patients (Martinez-Aran et al. 2009). These cognitive 
functions seem to worsen with illness progression (Kapczinski et al. 2008) and 
have a significant impact on general functioning. Cognitive impairments can be 
seen not only in bipolar patients but also in unaffected first-degree family members 
showing impairment in psychomotor performance speed and slight impairment 
in executive function. However, unaffected first-degree family members have 
normal performance in immediate memory, verbal fluency, and probably general 
intelligence (Robinson et al. 2006).
2.2.4 Overlap with related psychiatric disorders
BP and SCZ are recognized as separate disease entities with specific diagnostic 
criteria, but they share several clinical features and cognitive dysfunctions. Both 
disorders are highly heritable and are characterized by young ages at onset and 
a lifelong course. The disorders may include psychotic symptoms, but psychotic 
features are not always present in BP and predispose patients to increased risk for 
suicide (Berrettini 2003; Craddock et al. 2006; Moller 2003). 
Co-segregation in families of BP with SCZ has been reported in many studies 
(Berrettini 2003; Maier et al. 1993; Weissman et al. 1984). Moreover, psychotic 
symptoms like hallucinations and delusions have been found to aggregate in bipolar 
pedigrees (Potash et al. 2001). As many as 50 % of BP patients have been reported 
to experience at least one psychotic episode in their lifetime (Dunayevich and 
Keck 2000). Psychotic symptoms usually occur during manic episodes (Berrettini 
2003) and anti-psychotic drugs have been successful in decreasing the symptoms 
of both BP and SCZ (Tohen et al. 2003a; Tohen et al. 2003b; Tohen et al. 2003c). 
Many individuals with a severe psychiatric disorder have both mood and psychotic 
features falling between the diagnostic criteria of BP and SCZ, and thus are often 
diagnosed with schizoaffective disorder. This suggests that there may not be a neat 
biological distinction between these two disease entities. 
Although bipolar and unipolar (UPD) disorders are not completely distinct 
disease entities, their distinction for the purposes of diagnosis and research is 
supported by evidence from their clinical features, epidemiological studies and 
treatment (Farmer and McGuffin 1989; Kendell 1987). In contrast to BP, UPD is 
more common, women have two-fold the prevalence of men and age of onset is 
later than in BP. Family studies have provided evidence of familial aggregation 
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of UPD and the results of twin and adoption studies suggest a moderate genetic 
component in UPD, having a heritability estimate of 33-42 %. Co-segregation 
in families of BP with UPD has been reported in many studies (Berrettini 2003; 
Maier et al. 1993; Weissman et al. 1984) showing a significantly higher prevalence 
of UPD in BP families (Joyce et al. 2004). However, according to the concept of 
continuity in mood disorders mania, hypomania, depression, mixed states and 
mood temperaments are variants of the same disorder, and thus they should not be 
seen as dichotomized traits.
2.3 Genetics of bipolar disorder
The evidence from family and twin studies for the involvement of genes in the 
etiology of bipolar disorder is based on investigations of several thousands of 
individuals and the heritability seems to be stronger than for many other complex 
diseases. Nonetheless, finding genes underlying the genetic and neurobiological 
background of BP has proven to be challenging and they remain elusive. Strategies 
for pinpointing risk genes for BP include linkage and association approaches. 
2.3.1 Genome-wide linkage studies in BP
Several genome-wide scans have been conducted since the 1990s on a variety of 
sample sets of BP pedigrees, ranging from large densely affected pedigrees in isolates 
to large numbers of affected sibling pairs. Significant linkage findings on several 
chromosomal regions have been repeatedly implicated (Table 7). The strongly 
supported regions are 6q16–q22, 8q12q23–q24, 13q32–q34, 16p12–p13, 22q11–
q22 and Xq24–26 (Baron 2002; Craddock and Jones 1999; Craddock et al. 2005; 
Ekholm et al. 2003; Maziade et al. 2005). Conflicting results of the linkage findings 
have been attributed to genetic and phenotypic heterogeneity that increase the rates 
of both false-positive and -negative findings as well as lead to reduced statistical 
power. It is unclear which phenotype best captures the underlying mechanism of 
BP. Different diagnostic categories (narrowly defined BP, intermediate or broad 
spectrum of BP diagnostic categories) are used in linkage studies, and therefore 
many linkage findings may refer to different phenotypic subtypes of BP. 
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TABLE 7. Suggestive linkage findings in bipolar disorder (Caucasian population). 
Chromosome Region
1 p36.33, p36.11, p32.1, p31.1, q23.3, q31.3, q32.1, q42.13, q42.2, q44 
2 p25.1, p13.2, q11.2, q12.1, q14.1, q21.3, q24.1, q24.3, q31.1, q37.1, q37.3
3 p23, p21.32, p14.2, q23, q25.1, q26.31, q27.1, q28, q29 
4 p16.1, p14, q31.23, q35.1, q35.2 
5 p15.33, q32, q33.2, q33.3
6 p21.1, p23, q21, q23.3 
7 q22.1, q32.1, q36.1
8 p21.1, p12, q13.1, q13.2, q24.13, q24.22, q24.23, q24.3
9 p22.3–21.1, q21.13, q21.32, q31.1, q32, 
10 p12.33, q11.21–22.1, q21.3, q26.12, q26.2 
11 p15.5, q12.2
12 q13.12, q21.1, q23.1, q24.31, q24.32
13 q12.11, q12.3, q13.2, q14.2, q32.1, q32.2, q32.3, q33.3 
14 q24.1, q24.1–32.12, q22.2, q22.3, q32.33
15 q22.2, q26.2, q26.3
16 p13.3, p13.2. p13.13, p12.1, q12.2, q23.1
17 p12, q11.2, q25.3
18
p11.1–q12.3, p11.32, p11.31, p11.23, p11.22, p11.21, q12.1, q22.1. q22.3, 
q23
19 p13.3, q13.33
20 p13, p12.2, q13.13, q13.33 
21 q21.1, q22.2, q22.13, q22.3 
22 q11.1, q12.3
X p22.11, q22.3, q26.1, q27–28
Three meta-analyses of BP linkage have been published. The aim of the meta-
analyses was to identify and produce a more general understanding of the genetic 
predisposition to BP. Badner and Gershon examined seven published genome-
wide scans conducted worldwide (Badner and Gershon 2002). They established 
significant linkage to BP on chromosomes 13q and 22q. Similarly, Segurado et 
al. examined 18 genome-wide scans (Segurado et al. 2003). However, they did 
not find significant evidence for linkage in any of the analyses and there were no 
overlapping results with the previous meta-analysis study by Badner and Gershon. 
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The study by Segurado et al. provided only moderate support for chromosomal 
regions 9p22.3–21.1, 10q11.21–22.1, 14q24.1–31.12 and 18p–q. McQueen et al. 
conducted a combined analysis of 11 bipolar genome-wide scans by using original 
genome-scan data rather than summary statistics, as were used in the two previous 
meta-analyses. They found significant evidence for two susceptibility loci on 
chromosomes 6q and 8q (McQueen et al. 2005). Therefore, although meta-analyses 
provide some support for the genetic findings for BP, the genetic heterogeneity 
among different populations and samples is relatively high.
In the first Finnish linkage study of BP, microsatellite markers were analyzed 
on chromosome X. Linkage was found in an extended BP family and locus Xq24–
27.1 (LOD = 3.54) (Pekkarinen et al. 1995). On the locus Xq24–27.1 a distinct 
haplotype across a 19 centimorgan (cM) region was found to co-segregate with 
BP. Since new individuals from the extended family were added and diagnoses 
were updated, the extended family was re-analyzed separately from the other BP 
families (n = 40) in the fine-mapping study (Ekholm et al. 2002). When testing all 
41 families together, a LOD score of 2.78 was observed at Xq28. However, when 
the extended pedigree was excluded from the analysis, a LOD score of 1.34 was 
observed. The multipoint analysis gave a LOD score of 4.5 when only the extended 
family was analyzed, suggesting that a relatively rare gene predisposing to BP is 
enriched in the extended family (Ekholm et al. 2002). 
A genome-wide linkage scan with 389 microsatellite markers was conducted 
in 41 Finnish BP families. Three loci, 4q32, 12q23 and Xq25 produced LOD scores 
> 2.0 and one locus, 16p12, a LOD score >3.0 in two-point analyses. Loci 4q32, 
12q23 and 16p12 were fine-mapped with additional unaffected individuals from 
the 41 BP families. An X-linked extended pedigree was systematically analyzed 
separately from the other families. In a three-point analysis, locus 4q32 (LOD = 
3.6) and 16p12 (LOD = 2.7) provided significant evidence of linkage (Ekholm et 
al. 2003). This genome-wide scan was analyzed together in a meta-analysis with 17 
other genome-wide scans of BP conducted worldwide. Significant linkage was not 
reached in the analyses. However, some evidence of linkage on regions 8q, 9p–q, 
10q, 14q and 18p–q was observed in the meta-analysis (Segurado et al. 2003).
2.3.2 Candidate gene studies in BP
Two main approaches have been employed to identify genes in BP: the positional 
candidate gene approach, in which genes located under linkage peaks are selected 
for study; and the functional candidate gene approach, in which genes are selected 
based on their involvement in the biological processes implicated in the disease. 
Most BP functional candidate gene studies have focused on neurophysiologic 
alterations associated with the disease in animal models or pharmacological 
studies (Craddock and Jones 1999; Craddock and Jones 2001b). Both positive and 
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negative associations have been reported for candidate genes (Table 8), as seen in 
the association studies of other psychiatric disorders.
The imbalance or defective function of the monaminergic neurotransmitter 
system is related to the etiopathogenesis of BP. Consequently, some of the most 
widely investigated genes in BP have been those related to amine metabolism, such 
as catechol-O-methyltransferase (COMT) on 22q11.21 and monoamine oxidase 
A (MAOA) on Xp11.3. COMT encodes for an enzyme that catalyzes the degration 
of catecholamines, including dopamine, epinephrine and norepinephrine; while 
MAOA encodes a protein that oxidizes neurotransmitters, such as serotonin, 
dopamine and norepinephrine. To date, results for both genes have been 
controversial with positive association findings along with perhaps an even greater 
number of negative replications (Abdolmaleky et al. 2006; Anguelova et al. 2003; 
Lasky-Su et al. 2005b; Prata et al. 2006; Preisig et al. 2000; Serretti et al. 2006). 
Variants within COMT have been found to be associated with BP (Chen et al. 
2004; Shifman et al. 2004), and in addition with various cognitive functions (Egan 
et al. 2001; Ehlis et al. 2007; Goldberg et al. 2003; Harris et al. 2005) in several 
samples, including one from the Finnish population (Soronen et al. 2008). A CA-
repeat microsatellite in intron 2 has been consistently associated with BP in both 
Caucasian and Asian populations (Furlong et al. 1999; Lin et al. 2000). Another 
variant in the promoter of MAOA was found not associated in BP in Asian and 
Caucasian populations, except in one study on five pooled samples (Preisig et 
al. 2000). One study in Caucasians has recently reported association with BP of 
the haplotype composing of both the CA-repeat microsatellite and the promoter 
variant (Muller et al. 2007). 
Serotonin transporter (SLC6A4) and neuronal tryptophan hydroxylase (TPH2) 
have also been widely studied in BP. The SLC6A4 gene is located on 17q11.1–q12, 
which is has been positively linked to BP in two independent studies (Murphy 
et al. 2000; Tomas et al. 2006). A 48 base-pair promoter polymorphism has been 
associated with BP and four meta-analyses confirmed the finding (Anguelova et 
al. 2003; Cho et al. 2005; Furlong et al. 1998; Lasky-Su et al. 2005a). The TPH2 
gene on 12q21.1 encodes a rate-limiting enzyme in the biosynthesis of serotonin 
in the central nervous system (Walther and Bader 2003). Variants within the gene 
have consistently been associated with BP in seven independent studies (Cichon et 
al. 2008; Grigoroiu-Serbanescu et al. 2008; Harvey et al. 2007; Harvey et al. 2004; 
Lopez et al. 2007; Roche and McKeon 2009; Van Den Bogaert et al. 2006). However, 
two studies have reported negative findings (De Luca et al. 2004; Mann et al. 2008).
The D-amino acid oxidase activator DAOA (G72 /G30) locus is located on 
chromosome 13q22–34 where genes G72 and G30 overlap, but are transcribed in 
opposite directions. DAOA is a primate-specific gene encoding a mitochondrial 
protein that promotes mitochondrial fragmentation and dendritic branching. It 
is expressed in the central nervous system, in amygdala and caudate in particular 
(Craddock and Forty 2006). DAOA is involved in glutamate signalling playing a 
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role in the activation of N-methyl-D-aspartate receptors (Chumakov et al. 2002; 
Williams et al. 2006), which have been shown to have multiple effects on learning 
and memory. There have been at least five positive family-based association reports 
in two US BP family samples, which were replicated in another US family sample 
and two BP case-control association studies using German and UK samples (Chen 
et al. 2004; Hattori et al. 2003; Schulze et al. 2005; Schumacher et al. 2004; Williams 
et al. 2006). The Finnish bipolar family study sample showed marginal evidence for 
association of variants from DAOA with bipolar spectrum disorder (Soronen et al. 
2008), but a significant association with visuospatial ability. Interestingly, the same 
variant (Arg30Lys) associated in another study with verbal memory function in 
schizophrenia (Donohoe et al. 2007)..
The brain derived neurotrophic factor (BDNF) gene is a member of the 
neurotrophin superfamily. This gene plays an important role in promoting and 
modifying growth; the development and survival of neuronal cell populations; and 
the mature central nervous system. It is also involved in activity-dependent neuronal 
plasticity and connectivity in the central nervous system. The change in the function 
and structure of these processes may be induced by stress and antidepressants, and 
therefore BDNF could play an important role in mood disorders. The BDNF gene is 
located on chromosome 11p13, which has been implicated in some linkage analyses 
of BP (Green and Craddock 2003). This gene and particularly the Val66Met variant 
have consistently associated with BP and memory impairments (Martinez-Aran et 
al. 2004; Rybakowski et al. 2003; Rybakowski et al. 2006; Tramontina et al. 2009) in 
a total of eleven studies of mainly Caucasians (Geller et al. 2004; Green et al. 2006; 
Lohoff et al. 2005b; Neves-Pereira et al. 2002; Schumacher et al. 2005; Sklar et al. 
2002; Strauss et al. 2004). There have also been positive family-based association 
reports in BP samples of European-American origin (Kremeyer et al. 2006). These 
studies have shown the over-transmission of the common Val allele and there is 
also evidence of associated multilocus haplotypes in this gene. Controversely, six 
association studies in Caucasian, Japanese and Chinese populations have reported 
negative evidence for association (Green et al. 2006; Lohoff et al. 2005a; Nakata et 
al. 2003; Oswald et al. 2004; Skibinska et al. 2004). 
The purinergic receptor ligand-gated ion-channel 7 gene (P2RX7) encodes 
the P2X7 receptor, which is a non-specific cation channel that is activated by high 
levels of ATP. It has a role in neurotransmitter release and inflammatory responses. 
P2RX7 is located on 12q24, which has been previously implicated by several linkage 
studies of BP (Curtis et al. 2003; Dawson et al. 1995; Ekholm et al. 2003; Ewald et 
al. 1998; Maziade et al. 2001; Morissette et al. 1999; Shink et al. 2005) and UPD 
(Abkevich et al. 2003; McGuffin et al. 2005; Zubenko et al. 2003). More recently, a 
non-synonymous variant within P2RX7 has been reported to associate with BP in 
two independent studies (Barden et al. 2006; McQuillin et al. 2009) and with UPD 
(Hejjas et al. 2009; Lucae et al. 2006). Nonetheless, Green et al. studied 1,723 cases 
of BP and UPD and 1,204 controls from the UK population as well as sequenced 
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two BP families that previously showed linkage to the 12q23–24 region, and they 
failed to find evidence to support the association of P2RX7 with BP or UPD (Green 
et al. 2009).
The Disrupted-in-Schizophrenia-1 gene (DISC1) encodes a multifunctional 
protein that plays important roles in neurodevelopment and synaptic modulations 
by interacting with several proteins. It is highly expressed in the central nervous 
system, particularly in the hippocampus and the cerebral cortex (Austin et al. 
2003; Ozeki et al. 2004; Schurov et al. 2004). The genomic locus was originally 
identified and linked with SCZ and related psychiatric disorders in a large Scottish 
pedigree. Members of that large family carried a balanced (1;11) (q42.1;q14.3) 
translocation that segregated with major psychiatric disorders, including SCZ, BP 
and recurrent major depression. The translocation disrupts two genes, DISC1 and 
DISC2, at 1q42 (Blackwood et al. 2001; Millar et al. 2000a; Millar et al. 2000b). 
In recent years, the evidence for linkage and association of BP with DISC1 has 
been accumulating (Curtis et al. 2003; Detera-Wadleigh et al. 1999; Gejman et al. 
1993; Hodgkinson et al. 2004; Macgregor et al. 2004; Maeda et al. 2006; Thomson 
et al. 2005). Overtransmission of a risk haplotype to affected BP females, who 
also showed lower levels of DISC1 messenger RNA (mRNA) expression in their 
lymphoblast’s, was reported in a recent family-based association study (Maeda 
et al. 2006). A recent study revealed the presence of locus heterogeneity and the 
interplay of variants within DISC1 in the aetiology of major psychiatric disorders 
(Hennah and Porteous 2009).
The circadian locomotor output cycles kaput gene (CLOCK) appears to be 
involved in the regulation of the circadian rhythm. A variant in the 3´ flanking 
region of CLOCK (3111 T to C) has associated with a higher recurrence rate of 
bipolar episodes (Benedetti et al. 2003), greater insomnia and a decreased need for 
sleep in bipolar patients (Serretti et al. 2003; Serretti et al. 2005). In addition, other 
members of the molecular clock have been implicated in BP. Period homolog 3 
(PER 3) and Aryl hydrocarbon receptor nuclear translocator-like (ARNTL) genes 
have associated with BP (Mansour et al. 2006; Nievergelt et al. 2006). Interestingly, 
ARNTL encodes the protein Arntl that dimerizes Clock protein and Clock-Arntl 
heterodimers further seem to drive the PER 3 oscillations (Gekakis et al. 1998). 
Recently, haplotypes in BMAL1 and Per3 were found to significantly associate with 
BP (Nievergelt et al. 2006) and variants in BMAL1 and in the Timeless gene have 
also positively associated with BP (Mansour et al. 2006).
One of the promising candidate genes in BP is the glycogen synthase kinase 
3-β gene (GSK3β), which modulates the circadian clock and is the target of lithium 
(Gould and Manji 2005). GSK3β encodes glycogen synthase kinase 3B, a proline-
directed serine-threonine kinase that participates in the wnt signalling pathway 
and is involved in energy metabolism, neuronal development and body pattern 
formation (Serretti and Mandelli 2008). This gene and particularly the T-50C 
variant have associated with a later age of onset of BP, total sleep deprivation and 
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chronic lithium treatment (Benedetti et al. 2004; Benedetti et al. 2005). To date, 
results for this gene have been controversial with positive association findings along 
with negative replications (Lee et al. 2006; Michelon et al. 2006; Szczepankiewicz et 
al. 2006a; Szczepankiewicz et al. 2006b). However, recent CNV studies of BP have 
reported increased duplication of this region (Lachman et al. 2007).
A large number of candidate genes, including functional and positional 
candidate genes have been evaluated. Several of these genes have been associated 
with the disorder in independent studies (including BDNF, DAOA, DISC1, SLC6A4 
and TPH2), but none of their explicit roles have been established. The clinical 
heterogeneity of BP and its phenotypic and genetic overlap with other psychiatric 
disorders including in particular schizophrenia, schizoaffective disorder and major 
depressive disorder, cause problems for genetic studies. Affected patients may not 
share the same underlying biology, and therefore the use of endophenotypes, such 
as neuropsychological performance, would be a more optimal phenotype definition 
for genetic studies. 
TABLE 8.The most widely studied and associated genes with bipolar disorder.
Gene Function Location
ANK3a
Plays key roles in activities such as cell motility, activation, 
proliferation, contact and the maintenance of specialized 
membrane domains
10q21
ARNTL Encodes a protein that forms a heterodimer with CLOCK 11p15
BDNF Promotes the survival of neuronal populations 11p13
CACNA1Ca
Encodes an alpha-1 subunit of a voltage-dependent calcium 
channel that mediate the influx of calcium ions into the cell 
upon membrane polarization
12p13
CLOCK Encodes a protein that forms a heterodimer with ARNTL 4q12
COMT
Encodes catechol-O-methyl transferase; catalyses the 
O-methylation and inactivation of catecholamine 
neurotransmitters and catechol hormones
22q11
CREB1
Encodes a transcriptional activator that binds to the cAMP 
response element
2q33
DAOA
Encodes an activator of the FAD-dependent enzyme D-amino 
acid oxidase, which degrades the gliotransmitter D-serine, a 
potent activator of NMDA type glutamate receptors
13q22–34
DFNB31a
Interacts with a CASK, and may be involved in the formation 
of scaffolding protein complexes that facilitate synaptic 
transmission in the central nervous system
9q32–34
DGKHa
Encodes a type 2 diacylglycerol kinase (DGK) enzyme that 
is involved in regulating the intracellular concentrations of 
diacylglycerol and phosphatidic acid
13q14
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Gene Function Location
DISC1
Encodes an integral component of the pericentriolar 
material
1q42
DPY19L3a Encodes Dpy-19-like protein 3 19q13
GSK3β
Encodes glycogen synthase kinase 3β, a proline-directed 
serine-threonine kinase that participates in the wnt 
signalling pathway
3q13
HTR1A Encodes the type 1A receptor for 5-HT 5q12
HTR1B Encodes the type 1B receptor for 5-HT 6q14
HTR2A Encodes the type 2A receptor for 5-HT 13q14
MAOA
Encodes the monoamine oxidase A enzyme that degrades 
amine neurotransmitters, such as dopamine, noradrenaline 
and 5-HT
Xp11
MYO5Ba
Encodes a protein that may be involved in plasma membrane 
recycling
18q21
NAP5a
Interacts with the SH3-containing region of the adapter 
protein Nck
2q21
NTRK2a
Encodes a neurotrophic tyrosine receptor kinase (NTRK) that 
upon neurotrophin binding phosphorylates itself. NTRK is a 
member of the MAPK pathway
9q21
P2RX7 Encodes an ATP-gated cation channel 12q24
PALB2a
Binds to and colocalizes with the breast cancer 2 early 
onset protein (BRCA2) and permits the stable intranuclear 
localization and accumulation of BRCA2
16p12
PER3
Encodes a protein that plays a role in the circadian rhythms 
of locomotor activity, metabolism, and behavior
1p36
SLC642
Encodes an amine transporter and terminates the action 
of noradrelanine by its high-affinity sodium-dependent 
reuptake into presynaptic terminals
16q12
SLC6A4
Encodes an amine transporter and terminates the action of 
5-HT by its high-affinity sodium-dependent reuptake into 
presynaptic terminals
17q11
TPH2
Encodes neuronal tryptophan hydroxylase, the rate-limiting 
enzyme in the synthesis of 5-HT
12q21
a Genes significantly associated in genome-wide association studies in bipolar disorder.
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2.3.3 Genome-wide association studies in BP
In the last years, progress in the development of public databases, analysis methods 
and high-throughput genotyping technology has enabled large-scale genome-
wide association tests with common, complex diseases. The GWAS approach has 
revealed many variants that show consistent association with complex disorders, 
such as type 2 diabetes (Saxena et al. 2007), Crohns’s disease (Rioux et al. 2007), 
prostate cancer (Gudmundsson et al.2007) and schizophrenia (Shi et al. 2009; 
Stefansson et al. 2009). Recently, several groups have reported GWAS findings for 
bipolar disorder (Table 8) using either pooled (Baum et al. 2008) or individually 
genotyped samples (Baum et al. 2008; Ferreira et al. 2008; Scott et al. 2009; Smith 
et al. 2009; The Wellcome Trust Case Control Consortium 2007). The Wellcome 
Trust Case Control Consortium (WTCCC) studied 1,838 cases of BP and 2,938 
controls from the UK using the Affymetrix 500K GeneChip (The Wellcome Trust 
Case Control Consortium 2007)t. This large study reported only one genome-
wide significant association on 16p12 (rs420259, P = 6.3 × 10-8) that passed their 
stringent criteria for genome-wide significance (P  =  5  ×  10-7)(The Wellcome 
Trust Case Control Consortium 2007). Baum et al. revealed the most significant 
association with variants in the diacylglycerol kinase (DGKH) gene at 13q14.11 
(rs1012053 in intron 1, P = 1.5 × 10-8) in two sample sets, one German (772 cases 
and 876 controls) and the other from the US (NIMH collection: 461 cases and 563 
controls), by genotyping pooled DNA for 550K SNPs (Baum et al. 2008). In 1,461 
cases and 2,008 controls from a US Caucasian population using the Affymetrix 
500K GeneChip, Sklar et al. detected the strongest association with a variant 
in Myosin 5B (MYO5B) on 18q21.1 (P = 1.7 × 10-7), as well as association with 
tetraspanin-8 (TSPAN8) on 12q21.1 and epidermal growth factor receptor (EGFR) 
on 7p11.2, (Sklar et al. 2008).
There was no overlap of the most significant results between the studies of the 
WTCCC and Baum et al. when in-depth comparison was performed (Gershon et 
al. 2008), nor was there an overlap between the studies of Baum et al. and Sklar et 
al. (Sklar et al. 2008). However, when Sklar et al. compared their top 200 SNPs with 
the WTCCC results they observed a consistency with a variant in the alpha 1C 
subunit of the L-type voltage-gated calcium channel (CACNA1C) gene on 12p13.33 
(Sklar et al. 2008). The lack of overlap of the most significant results among these 
three studies may be due to different study designs, genetic heterogeneity, or the 
fact that variants may have relatively modest effects on susceptibility to BP and are 
not easily detected.
In order to validate genome-wide significant association results, Ferreira et 
al. studied 4,387 cases of BP and 6,209 controls by combining the results of two 
previously studies, the WTCCC and Sklar et al. studies, and one new GWAS (1,098 
cases of BP and 1,267 controls) using 1.8 million variants (Ferreira et al. 2008). 
This meta-analysis identified a region of strong association in ankyrin G (ANK3) 
on 10q21 (rs10994336, P = 9.1 ×  10-9). In addition, they found further support 
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for the association in the CACNA1C region on 12p13 (rs1006737, OR = 1.18, 
P = 7.0 × 10-8). 
Smith et al. conducted GWAS studies in two sample sets: one of European 
ancestry (n = 1,001 cases and n = 1,033 controls) and the other of African 
ancestry (n =345 cases and n = 670 controls). For the European ancestry sample, 
the strongest evidence for association maps to an intergenic region on Xq27.1 
(rs5907577, P  =  1.6  ×  10-6) and the Nck-associated protein 5 gene (NAP5) on 
2q21.2 (rs10193817, P = 9.8 × 10-6). For the African Ancestry sample, the strongest 
association was detected with a variant in the dpy-19-like 3 gene (DPY19L3) on 
19q13.11 (rs2111504, P = 1.5 × 10-6) and the neurotrophic tyrosine kinase receptor 
type 2 gene (NTRK2) on 9q21.33 (rs2769605, P = 4.5 × 10-5). However, significant 
genome-wide association was not detected in either of the sample sets. Some 
support for the previous association in ANK3 and C15Orf53 at the 15q14 region 
was found (Smith et al. 2009). The most recent GWAS with 2,076 BP cases and 
1,676 controls of European ancestry using the Illumina 550K chip and data for >2.3 
million genotyped and imputed variants did not provide support for the previous 
BP GWAS findings. In addition, they performed a 3-study meta-analysis with the 
previously published (WTCCC) BP study (n = 3,683 cases and 14,507 controls), 
but there were no genome-wide significant associations (Scott et al. 2009).
GWAS results strongly suggest that BP is influenced by the effects of multiple 
rare variants rather than common variants that would be shared by many 
populations. The strong heritability of BP and the relative lack of the shared risk 
variants suggest that there are few, if any, common risk variants on bipolar disorder.
2.3.4 Copy number variation studies in BP
Recent analysis of copy number variations (CNVs) has shown that a considerable 
number of neuropsychiatric disorder candidate genes have their coding elements 
disrupted by polymorphic CNVs, which suggests they have a substantial 
contribution to disease. The first CNV study in BP revealed a CNV in the GSK3β 
locus on 3q13.3 with increased frequency in BP patients compared to controls 
(P = 0.002). The finding suggests that GSK3β may be involved in BP susceptibility 
in some individuals (Lachman et al. 2007). The systematic genome-wide CNV 
analysis of BP (n = 1,001 cases and 1,033 controls) showed that singleton deletions 
induce a 1.31-fold increased risk of BP and singleton deletions more than 100 kb 
were present in 16.2 % of BP cases in contrast to 12.3 % of controls (P = 0.007). The 
effect was even greater among patients with earlier onset of mania. These results 
suggest that very rare de novo deletion events increase risk of BP (Zhang et al. 
2009). In addition, a recent meta-analysis of datasets gathered for the study of 
multiple psychiatric disorders showed an association of the microduplication of 
a 600 kb genomic region on 16p11.2 with schizophrenia (P = 4.8 x 10-7), bipolar 
disorder (P = 0.017) and autism (P = 1.9 x 10-7) (McCarthy et al. 2009).
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3	 Aims	of	the	study
The aim of the present study was to investigate the genetic basis of BP and to identify 
susceptibility genes for BP and related cognitive features in Finnish families. The 
following specific aims of this study were: 
1.  To examine the role of the allelic variants of the TSNAX/DISC1 gene 
cluster in psychotic and bipolar spectrum disorders and related cognitive 
endophenotypes.
2.  To examine the role of the widely studied six candidate genes (SLC6A4, TPH2, 
BDNF, CREB1, NTRK2 and P2RX7) from three seemingly distinct signalling 
systems in the genetic background of psychotic and bipolar spectrum disorders 
and related cognitive endophenotypes
3.  To identify genomic susceptibility regions to bipolar disorder by investigating 
bipolar families originating from the late settlement region of Finland.
4.  To elucidate the role of the allelic variants associating with bipolar disorder in 
the recent GWA studies.
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4	 Material	and	methods
4.1 Study sample (I, II, III and IV)
All Finnish families collected and ascertained for bipolar disorder were used in 
our study. The study sample consisted of 723 individuals including 298 affected 
with broad mood disorder in 179 families. 69 families altogether had two or more 
affected individuals with DNA samples available. The set of 179 families included 
44 dizygotic twins (with broad mood disorder n = 25) from 29 twin pairs and 6 
monozygotic twins (with broad mood disorder n = 6) from 6 twin pairs (Kieseppä 
et al. 2004). The diagnoses of individuals in 21 BP families of the 41 families 
included in previous bipolar genome-wide linkage scan analyses (Ekholm et al. 
2003) were ascertained and updated in 2003 using the Structured Clinical Interview 
method (SCID) (Antila et al. 2007a; Spitzer et al. 1997). The new method led to 30 
changes in diagnosis: 20 unknown cases were ascertained to have bipolar disorder 
or recurrent major depressive disorder (rMDD); and 10 cases of broad type bipolar 
disorder including BP-I, BP-II, bipolar disorder not otherwise specified (BP-NOS), 
cyclothymia and rMDD changed to schizophrenia or other non-bipolar psychoses. 
For studies I and III, two alternative diagnostic categories were applied 
comprising a group of patients with bipolar spectrum disorders, i.e. bipolar 
disorder type I, II, BP-NOS and cyclothymia (n = 227), and a group of patients with 
psychotic disorders, i.e. bipolar disorder type I with intermittent psychotic features, 
psychotic depression, schizophrenia, schizoaffective disorder and psychosis NOS 
(n = 251). There were 162 individuals belonging to both groups. In study III, the 
set of 118 families (n = 543) having at least two affected individuals was selected as 
a subsample in Table 9). For study II and IV, a group of patients with broad mood 
disorder, i.e. bipolar disorder type I, II and not otherwise specified, manic type 
of schizoaffective psychosis, cyclothymia, and recurrent depression, was used for 
analysis. In study IV, patients with bipolar disorder type I (n = 214) were studied. 
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TABLE 9. The composition of the study sample available for analysis
Total Males Females Familial 
cases
Neuropsycho-
logically  
assessed
Family samplea
Bipolar disorder 214 110 104 171 63
Bipolar spectrum 
disorderb,d
227 118 109 173 66
Psychotic disorderc,d 251 134 117 212 67
Other mental 
disorders
46 19 27 45 26
Unaffected family 
members 
361 153 208 241 51
Total 723 344 379 544 158
Control sample
Anonymous trio 
sample 
171 101 70 0 0
a The families were ascertained for BP through the nationwide register data. The family sample 
includes 44 dizygotic and 6 monozygotic twins.
b Includes cases with bipolar disorder type I (n = 214) , II (n = 5), not otherwise specified (n = 6) 
and cyclothymia (n = 2).
c Includes cases with bipolar disorder type I with intermittent psychotic features (n = 162), 
psychotic depression (n = 15), schizophrenia (n = 14), schizoaffective disorder (n = 51), and 
psychosis NOS (n = 9).
d Overlap of 162 affected individuals between the diagnostic categories. 
For study II, we selected 23 late settlement families with at least two affected 
siblings. Families of the late settlement were chosen according to the birthplaces 
of the siblings’ grandparents such that at least one grandparent from each family 
originated from the late settlement region of Finland. The late settlement families 
were selected for our various genetic analyses in distinct diseases, because the 
families originating from that region are, according to several genetic and population 
LD studies, genetically more homogenic than nation-wide samples (here the larger 
set of 179 families). The 23 families originating from the late settlement region 
consisted of 147 individuals from 21 nuclear families and two extended families. 
The largest extended family consisted of four generations with 18 affected subjects. 
The study sample included 68 affected individuals with a diagnosis of a broad mood 
disorder, i.e. bipolar disorder type I, II, or not otherwise specified, manic type of 
schizoaffective psychosis, cyclothymia, or recurrent depression (Table 10). The 
broad mood disorder model was used since unipolar disorder is the most common 
disorder in families with bipolar disorder. Of unipolar disorder patients, 12-41% 
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patients eventually develop mania or hypomania (Akiskal et al. 1995; Goldberg et 
al. 2001).
TABLE 10. The composition of the late settlement family sample of 23 families used for 
genome-wide linkage scan.
Family samplea Total Males Females
  Broad mood disorderb 68 39 29
  Other mental disorder 21 11 10
  Unaffected family members 58 24 34
  Total 147 74 73
Anonymous trio sample 0 0 0
a The families were ascertained for bipolar I disorder through nationwide register data.
b Includes cases with bipolar disorder type I (n = 214), bipolar disorder type II (n = 5), bipolar 
disorder not otherwise specified (n = 6), manic type of schizoaffective psychosis ( n = 46), 
cyclothymia (n = 2) and recurrent depression ( n = 25).
A random sample of 57 control families from the Finnish population 
consisting of three family members (father, mother and one child) was combined 
with the whole family sample for the association analysis in order to account for 
the ascertainment bias of the family sample.
4.2 Examined phenotypes
4.2.1 Clinical diagnosis (I–IV)
The bipolar family sample was collected utilizing The National Hospital 
Discharge Register in order to identify individuals born between 1940 and 1969 
and hospitalized with a diagnosis of BP between 1969 and 1991. The National 
Public Health Institute obtained permission from the Ministry of Social Affairs 
and Health to access data for the years 1968–1991 for genetic studies of mental 
disorders (Hovatta et al. 1997). The diagnoses in the Hospital Discharge Register 
were based on the International Classification of Diseases, version 8 (ICD-8) 
(WHO 1967) before 1987, and between 1987 and 1991 they were based on the 
Diagnostic and Statistical Manual of Mental Disorders, revised third edition (DSM-
III-R) (American Psychiatric Association 1987). From the register, we identified all 
patients with at least one diagnosis of bipolar disorder (296.10 or 296.30 (ICD-8), 
or 296.4, 296.5 or 296.6 (DSM-III-R)).
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Two psychiatrists assessed the diagnoses on the basis of the medical records, 
blind to each other and according to DSM-IV-criteria (American Psychiatric 
Association 1994). Diagnoses were discussed and, if needed, the opinion of a 
senior psychiatrist was obtained for the consensus. No disagreement remained. 
Only patients with bipolar disorder or the manic type of schizoaffective disorder 
were regarded as eligible probands. The latter diagnosis was accepted, because 
there is accumulating evidence that it might have a shared genetic background with 
bipolar I disorder (Kendler and Gardner 1998). The probands were then linked to 
family members by gathering information from the National Population Register. 
The Hospital Discharge Registry was used for the diagnosis of the probands’ family 
members. In addition, twins with a diagnosis of BP were identified and collected 
in the same manner as the family sample from the Finnish twin cohorts (Kieseppa 
et al. 2004).
4.2.2 Neurocognitive variables (I, II)
During 1999–2004, 158 (study II: 159) family members from 57 (study II: 65) nuclear 
and extended bipolar families completed a comprehensive neuropsychological test 
battery (Antila et al. 2007a; Antila et al. 2007b).
The neuropsychological test battery, from which the cognitive traits were 
obtained, is a series of tests that uses well validated, internationally well-known 
neuropsychological measures to evaluate an individual’s cognitive ability. The test 
includes Vocabulary, Similarities, Digit Symbol and Block Design subtests from the 
Wechsler Adult Intelligence Scale-Revised (WAIS-R)(Weschler 1981), which assess 
basic ability, abstraction, psychomotor processing speed and visuospatial ability, 
respectively. From the Wechsler Memory Scale-Revised (WMS-R)(Weschler 1987), 
we included: the Digit Span Forward and Backward tests, which measure auditory 
attention and verbal working memory, respectively; the Visual Span Forward 
and Backward tests, which assess visual attention and visual working memory, 
respectively; and the Logical Memory and Visual Reproduction subtests to assess 
verbal and visual memory, respectively, in both immediate and delayed conditions. 
The California Verbal Learning Test (CVLT) was included to assess (Delis DC 
1987) the following variables: learning (total recall from trials 1-5), short-delay 
memory, long-delay memory, recognition memory, retention and perseverative 
recall errors. Executive functioning and selective attention were assessed with the 
Colour-Word Interference Score from the Stroop test (Golden 1978). Phonemic and 
semantic verbal fluency was assessed with the Controlled Oral Word Association 
Test (COWAT) (Benton A 1989), which can also be considered a measure of 
executive functioning. The neuropsychological test battery was administered by 
psychologists or advanced psychiatric nurses extensively trained and supervised in 
using the test battery. Experienced psychologists scored all the tests.
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4.3 Ethical aspects
The genetic studies of the bipolar disorder were approved by the Ministry of Social 
Affairs and Health and the Ethics Committee of the National Public Health Institute. 
All patients and family members gave full informed consent and all blood samples 
were taken in accordance with the Helsinki Declaration and its amendments.
4.4 Laboratory methods and statistical   
 analysis
Descriptions of the methods used in the present study can be found in the original 
articles (I–IV), as described in Table 11.
TABLE 11. Methods used in the present study
Material or Method Original Publication
Study samples
Family sample I, II, III, IV
Late settlement sample III
Control sample I, III
Laboratory procedures and measurements
DNA extraction I, II, III, IV
DNA sample quality control III
Spectrophotometry III
PicoGreen measurements I, III
Polymerase chain reaction (PCR) I, II, III, IV
Whole genome amplification I, II, III, IV
Agarose gel electrophoresis I, II, III, IV
Sequenom MALDI-TOF Mass Spectrometry I, II, III, IV
Multiply-primed rolling circle DNA amplification III
Illumina genotyping system III
Analysis programs
Sequenom SpectroDesigner (version 1.3 and 2.0) I, II, III, IV
Sequenom SpectroTyper RT (version 2.0) I, II, III, IV
Pedcheck v.1.1 I, II, III, IV
Table continues
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Material or Method Original Publication
Statistical methods and programs
SAS 9.1 for windows III
SNP selection I, II, III, IV
MLINK/LINKAGE 4.1P III
Analyze II, III
Genehunter v2.1_r6 III
FBAT v.1.7.3. (HBAT) I, II, III, IV
Haploview v4.0 II, III
Transmit 2.5.4. I
QTDT I, II
Simwalk 2.81 I, II, III
Pseudomarker I
4.4.1 DNA extraction and quality control
DNA was extracted from Ethylenediaminetetraacetic acid (EDTA)-treated blood 
according to manufacturer’s instructions with the Puregene DNA purification 
system (Gentra systems, Minneapolis, Minnesota, USA). Stock DNA samples were 
diluted in a concentration of 20 ng /µl using Tecan GenesisRSP150 (PLO, Espoo, 
Finland). The concentration of the diluted DNA was quantified with the Quant-
IT Pico Green dsDNA Assay Kit (Eugene, Leiden, Netherlands) and corrected if 
necessary. We determined the sex of DNA samples with sex chromosomal markers 
and excluded all samples with discrepant results. Furthermore, we genotyped 
autosomal microsatellite markers to identify contaminated samples and confirm 
the relationships of the family members (unpublished data).  
4.4.2 Candidate genes and marker selection
Study I focused on the TSNAX/DISC1 gene cluster and study II on bipolar candidate 
genes; BDNF, CREB1, NTRK2, SLC6A4, TPH2 and P2RX7. Genotyped variants of 
the TSNAX/DISC1 gene cluster are shown in Figure 6. In study II, all the variants 
of the genes investigated are listed in Table 12. In study III, the Illumina Panel IV 
(6K) Array, which includes 5663 SNPs distributed across the 22 autosomes and 345 
SNPs in the X and Y chromosomes, was used. In study IV, the best associating SNPs 
Table continues
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were selected from the Welcome Trust Case Control Consortium with p-values of 
p < 0.000054, from Baum et al. with p-value < 0.0001 and from their meta-analysis. 
Genotyped variants are listed in the Table 13.
FIGURE 6. The schematic overview of the TSNAX/DISC1 region. The exonic structure of the 
TSNAX (grey boxes) and DISC genes (black boxes), and analyzed markers and haplotypes 
are shown in relationship to the intergenic exons (white boxes). Modified from Hennah et 
al. 2003. Reproduced with a permission of the copyright holder.
TABLE 12. Minor allele frequencies, alleles and positions of the analyzed candidate genes’ 
SNPs (study II).
SNP
Tag SNP 
coveragea
Chr Position Location Allelesc MAF
BDNF 5/5 (1.0)
rs11030096 11 27622119 3’ downstream T/C 0.48
rs2203877 11 27627486 3’ downstream T/C 0.48
rs6265 11 27636492 Exon (Val66Met) C/T 0.14
rs11030102 11 27638172 Intron C/G 0.24
rs11030108 11 27652040 Intron G/A 0.34
rs6484320 11 27659764 Intron A/T 0.17
rs2049046 11 27680351 Intron T/A 0.47
rs7934165 11 27688559 Intron G/A 0.48
rs1491850 11 27706301 5’ upstream T/C 0.43
rs1491851 11 27709339 5’ upstream C/T 0.42
Table continues
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SNP
Tag SNP 
coveragea
Chr Position Location Allelesc MAF
CREB1 2/3 (0.67)
rs2709366 2 208200569 5’ upstream C/A 0.19
rs2709376 2 208215894 5’ upstream C/T 0.03
rs2709356 2 208237598 1. intron C/T 0.14
rs2709359 2 208240643 1. intron G/A 0.03
rs2709402 2 208246483 2. intron C/A 0.13
rs10932201 2 208251763 4. intron G/A 0.48
rs11904814 2 208252304 4. intron T/G 0.35
rs2551921 2 208261061 6. intron T/C 0.13
rs2709387 2 208267601 7. intron G/A 0.14
NTRK2 3/31 (0.09)
rs1147199 9 86465715 5’ upstream G/A 0.17
rs1025743 9 86504937 1. intron C/T 0.43
rs1187362 9 86528087 4. intron A/T 0.25
rs1573219 9 86577442 10. intron G/A 0.23
rs1047896 9 86615793 11. exon (3’ UTR) A/G 0.19
rs11140767 9 86615874 11. exon (3’ UTR) G/A 0.01
rs730240 9 86619183 11. exon (3’ UTR) C/T 0.00
rs3654 9 86620311 11. exon (3’ UTR) T/C 0.07
rs7038236 9 86678222 14. exon (3’ UTR) C/A 0.14
rs11140793 9 86681300 14. exon (3’ UTR) A/C 0.13
rs1221 9 86682430 14. exon (3’ UTR) C/T 0.13
rs736744 9 86704227 14. intron T/C 0.46
rs4410985 9 86799073 17. intron T/C 0.42
rs729560 9 86824125 18. intron A/G 0.42
rs3739570 9 86827398 20. exon (3’ UTR) G/A 0.14
SLC6A4 4/4 (1.0)b
rs7224199 17 25547852 3’ near gene G/T 0.39
rs3794808 17 25555919 13. intron C/T 0.37
rs140701 17 25562658 9. intron C/T 0.37
rs140700 17 25567515 6. intron C/T 0.11
rs6354 17 25574024 2. exon (5’ UTR) T/G 0.19
rs4251417 17 25575984 1. intron C/T 0.07
rs2020930 17 25590167 5’ upstream C/T 0.02
Table continues
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SNP
Tag SNP 
coveragea
Chr Position Location Allelesc MAF
TPH2 8/10 (0.8)
rs11178997 12 70618420 5’ near gene T/A 0.08
rs10748185 12 70622122 2. intron A/G 0.49
rs10879344 12 70630828 4. intron A/T 0.02
rs1386494 12 70638810 4. intron C/T 0.19
rs1386492 12 70648532 6. intron T/C 0.25
rs1843812 12 70653922 7. intron G/A 0.19
rs7305115 12 70659129 8. exon G/A 0.46
rs7954332 12 70662605 8. intron G/A 0.19
rs1386497 12 70678557 9. intron A/C 0.20
rs12229394 12 70679181 9. intron G/A 0.33
rs4760820 12 70683263 9. intron C/G 0.36
rs10879354 12 70696049 9. intron C/T 0.47
rs1487275 12 70696559 9. intron A/C 0.39
rs4290270 12 70702502 10. exon A/T 0.48
rs1872824 12 70716581 3’ downstream G/A 0.37
P2RX7 6/13 (0.46)
rs7310821 12 120051568 5’ upstream C/T 0.09
rs591874 12 120055848 1. intron A/C 0.34
rs1718125 12 120077402 2. intron C/T 0.14
rs208290 12 120078439 4. intron G/A 0.37
rs208294 12 120084636
6. exon 
(His155Tyr)
C/T 0.39
rs208298 12 120086621 6. intron G/A 0.31
rs504677 12 120089572 8. intron C/T 0.47
rs1718119 12 120099486
12. exon 
(Ala348Thr)
G/A 0.45
rs2230912 12 120106579
14. exon 
(Gln460Arg)
A/G 0.18
rs2303998 12 120139446 3’ downstream G/A 0.00
a Tag SNPs defined by the multimarker option with cut off values of 0.2 for minor allele frequency 
and 0.8 for r2 in the HapMap database.    
b Cut off value of 0.1 for minor allele frequency.
c Major allele listed first.
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TABLE 13. Minor allele frequencies, chromosomal positions and the replication sources of 
the analyzed SNPs (study IV).
Gene/Region SNP Chr Replication Alleles
1p31 rs2989476 1 WTCCC G/C
TCF7L1 rs6732834 2 Baum et al. C/T
DPP10 rs1375144 2 WTCCC A/G
CMTM8 rs4276227 3 WTCCC C/T
LAMP3 rs683395 3 WTCCC A/G
SORCS2 rs4411993 4 Baum et al. C/T
SORCS2 rs7683874 4 Baum et al. G/A
SORCS2a rs10937823 4 Baum et al. C/T
6p21.1 rs6458307 6 WTCCC C/T
GABBR2 rs3802477 9 Baum et al. T/C
DFNB31a rs10982256 9 WTCCC C/T
DFNB31 rs942518 9 Baum et al. A/G
JAM3 rs10791345 11 Baum meta G/A
DGKHa rs9315885 13 Baum et al. T/C
DGKH rs1170191 13 Baum et al. G/A
NALCN rs9513877 13 Baum et al. G/A
TDRD9 rs11622475 14 WTCCC C/T
A2BP1 rs10500336 16 Baum et al. A/G
A2BP1 rs7204975 16 Baum et al. C/T
PALB2 rs420259 16 WTCCC A/G
16q12.2 rs1344484 16 WTCCC T/C
PLCG2 rs4586425 16 Baum et al. C/T
NXN rs2360111 17 Baum et al. C/T
FZD2 rs4792948 17 Baum et al. C/T
SLC39A3a rs4806874 19 Baum meta A/G
CDC25B rs3761218 20 WTCCC T/C
a Major allele listed first.
4.4.3 Genotyping and quality control
This study utilized two different SNP genotyping methods. Primarily, SNP 
genotyping was performed using Sequenom’s MassARRAY system (Sequenom 
Inc., San Diego, CA, USA) (I–IV). The primers for the SNP assays were designed 
using the SpectroDESIGNER software, versions 1.3 and 2.0 (Sequenom Inc., San 
Diego, CA, USA). SNP genotyping was performed following the manufacturer’s 
guidelines using, either the homogenous Mass Extension (hME) reaction or the 
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iPLEX reaction on the Sequenom MassARRAY System (Sequenom Inc.). The 
second genotyping method was the commercial Illumina Linkage Panel IV (6K) 
Array (Illumina, San Diego, CA, USA) (II). Arrays were scanned with the illumina 
BeadStation 500GX scanner and analyzed with Illumina BeadScan Version 2. The 
genotyping sample included eight duplicates and eight water control samples. All 
genotypes were checked for correct Mendelian transmission using PedCheck v1.1. 
(O'Connell and Weeks 1998). 
4.4.4 Statistical analysis
In study I, a single marker association test was performed using the pseudomarker 
program (Goring and Terwilliger 2000) and the ‘association given no linkage’ 
-option of the program. Haplotype analysis was conducted using the TRANSMIT 
2.5.4. program (Clayton 1999) for all affected individuals, and separately for 
affected females and affected males.
In studies I and II, we analyzed the association of the variants with the 
neuropsychological test variables using the Quantitive Transmission Disequilibrium 
test (QTDT) program (Abecasis et al. 2000). Age, sex and the presence of the 
psychosis were used as covariates. 100 000 permutations were performed to obtain 
empirical p-values. To test the associating haplotypes and quantitative traits, the 
haplotypes were constructed for each genotyped individual using the SimWalk2 
program (Sobel and Lange 1996). 
In studies II and IV, the single marker association test was performed using the 
haplotype relative risk (HRR) test of the ANALYZE package (Lathrop and Lalouel 
1984) and the family–based association test (FBAT) version 1.7.3. The haplotype 
extension (HBAT) of the FBAT program (Horvath et al. 2004) was used to test the 
association analysis of two – and three SNP haplotypes with the sliding window. 
The statistical comparisons of neuropsychologicals test results among selected 
genotyped groups were analyzed in SPSS 14.0 (SPSS Inc. Chigago, Illinois, USA) 
using one-way ANOVA.
In the genome-wide scan study (III), the data were analyzed using the 
AUTOGSCAN 1.0 program (Hiekkalinna and Peltonen 1999), which automates 
the use of the ANALYZE package (Lathrop and Lalouel 1984). An affected-only 
linkage analysis was performed with recessive and dominant models. Multipoint 
non-parametric linkage (NPL) analyses and haplotype analyses were conducted 
only for the regions showing the highest genome-wide significance using the 
Genehunter v2.1_r6 program (Kruglyak et al. 1996). Association analyses were 
conducted by FBAT version 1.7.3. using the single marker association test and the 
HBAT (Horvath et al. 2004) with the sliding window.
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5	 Results	and	discussion
5.1 Association analysis of the DISC1 gene (I)
Bipolar disorder and schizophrenia have at least partially convergent aetiology, 
even though they represent separate disease entities with specific diagnostic 
criteria. They share several clinical features and cognitive impairments. In addition, 
both diseases are found to co-segregate in many families. Although psychosis is a 
primary diagnostic criterion for SCZ, a large part of BP-I cases have intermittent 
psychotic symptoms. There is, possibly, a more complex relationship between the 
psychotic disorders and thus they may share some genetic susceptibility loci. A 
majority of studies have found evidence of the role of the DISC1 gene in psychotic 
disorders: SCZ, BP and schizoaffective disorder (Porteous et al. 2006). DISC1 
encodes an 854-amino-acid protein, which interacts with a variety of proteins 
known to be involved in several neuronal functions: cytoskeletal regulation, 
neuronal outgrowth and migration, and signal transduction (Kamiya et al. 2006; 
Morris et al. 2003). We attempted to identify whether DISC1 has an aetiological 
role in the genetic background of psychotic and bipolar spectrum disorders and 
related quantitative cognitive traits in Finnish BP families. We also analyzed SNPs 
in the TSNAX gene next to DISC1.
We looked for association of allelic variants in the TSNAX/DISC1 gene cluster 
using 13 SNPs across the 600-kb region in 723 individuals of 179 Finnish BP families. 
We used two diagnostic categories: psychotic disorder and bipolar spectrum 
disorder. Using psychotic disorder as an outcome, the strongest association was 
observed for the T-A haplotype of rs751229 and rs3738401 at the 5’ end of DISC1. 
The haplotype was over-transmitted to males with psychotic disorder (p = 0.008) 
and a rare extension of the haplotype, including the T-A-G alleles of rs751229, 
rs3738401 and rs1538977, respectively, was over-transmitted in affected males 
(p = 0.0007 with both genders and p = 0.007 for males alone). This finding was 
consistent with earlier studies in Finnish schizophrenia families (Hennah et al. 
2005; Hennah et al. 2003). Another allelic haplotype of the same variants was also 
overtransmitted to males (p = 0.001 for C-G-A allele combination). 
With bipolar spectrum disorder as an outcome, we found a major haplotype of 
rs1630250 and rs1615409 within the TSNAX gene to be over-transmitted in affected 
females and males (p = 0.007 global and for G-C alleles p = 0.007). The signal for 
association was found to be derived from bipolar spectrum individuals without 
psychotic features (p = 0.0014 global and for females p = 0.00001). A haplotype at 
the 3’ end of DISC1 associated with bipolar spectrum disorder (p = 0.0002) with 
the T-T alleles of rs821616 and rs1411771 under-transmitted in both females and 
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males. An extended haplotype of rs821616, rs1411771 and rs980898 was under-
transmitted in both genders with the T-T-G alleles (p = 0.0001). The signal for 
this haplotype was derived from individuals of bipolar spectrum disorders with 
or without psychotic features. These results support evidence of the association of 
common and rare haplotypes around the 5’ end of DISC1 with psychotic disorder 
in males. The results provide consistent evidence of association around the 5’end of 
TSNAX and the 3’ end of DISC1 with bipolar spectrum disorder.
We tested the association between the variants of the DISC1/TSNAX gene 
cluster and cognitive traits derived from the neuropsychological test battery in 158 
individuals from the BP families. The traits were selected based on the previous 
findings for DISC1, high heritability estimates of these traits in Finnish BP families 
and their suggested validity as endophenotypes of BP. The risk haplotype for 
psychotic disorder including rs751229 at the 5’ end of DISC1 also associated to 
perseverations (p = 0.035; for rs751229 alone p = 0.0012) and long delay recall (p 
= 0.0032). A protective haplotype of rs1655285, rs751229 and rs3738401 at the 
5’ end of DISC1 with G-T-G alleles was associated with auditory attention (p = 
0.0059). The 3’ end variants associated with several cognitive traits with the most 
robust signal between rs821616 and verbal fluency and rs980989 and psychomotor 
processing speed (p = 0.011 for both). Psychomotor processing speed is considered 
a strong and valid endophenotype for BP (Antila et al. 2007a; Antila et al. 2007b).
To conclude, these results support the involvement of DISC1 in the genetic 
aetiology of BP and suggest that its distinct variants contribute to variation in 
the dimensional features of psychotic and bipolar spectrum disorders in Finnish 
BP families. The alternative associating haplotypes found in the same set of BP 
families gives evidence for allelic heterogeneity within DISC1, which eventually 
leads to heterogeneity in clinical outcomes as well. The variants included in these 
associating haplotypes also displayed association with different cognitive traits 
(Table 14), proposing possible systems underlying the biology of BP. 
TABLE 14. The most significant association results of genes studied in this thesis.
Disorder Gene Variant or haplotype No. of 
affected 
Statistical 
method
p-value
Bipolar BDNFa rs1491851 227 FBAT 0.032
spectrum SLC6A4 rs3794808 227 FBAT 0.045
disorder SLC6A4 rs140700 227 FBAT 0.021
P2RX7 rs2230912 227 FBAT 0.048
BDNF rs7934165-rs1491850-rs1491851 227 FBAT 0.039
BDNF rs7934165-rs1491850-rs1491851 227 FBAT 0.010
BDNF rs1491850-rs1491851 227 FBAT 0.004
SLC6A4 rs7224199-rs3794808 227 FBAT 0.037
SLC6A4 rs3794808-rs140701 227 FBAT 0.043
Table continues
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Disorder Gene Variant or haplotype No. of 
affected 
Statistical 
method
p-value
SLC6A4 rs3794808-rs140701-rs140700 227 FBAT 0.029
SLC6A4 rs140701-rs140700 227 FBAT 0.029
SLC6A4 rs140701-rs140700-rs6354 227 FBAT 0.019
SLC6A4 rs140700-rs6354 227 FBAT 0.017
SLC6A4 rs140700-rs6354-rs4251417 227 FBAT 0.028
P2RX7 rs208290-rs208294-rs208298 227 FBAT 0.032
P2RX7 rs208290-rs208294-rs208298-rs504677 227 FBAT 0.006
P2RX7 rs208290-rs208294-rs208298-rs504677 227 FBAT 0.024
P2RX7 rs208294-rs208298 227 FBAT 0.039
P2RX7 rs208294-rs208298-rs504677 227 FBAT 0.010
DISC1a rs1630250-rs1615409 227 TRANSMIT 0.007
DISC1 rs1000731-rs821616 227 TRANSMIT 0.025
DISC1 rs821616-rs1411771 227 TRANSMIT 0.004
DISC1 rs6675281-rs1000731-rs821616 227 TRANSMIT 0.033
DISC1a rs821616-rs1411771-rs980989 227 TRANSMIT 0.021
Psychotic BDNF rs2049046-rs7934165-rs1491850 251 FBAT 0.015
disorder BDNF rs7934165-rs1491850 251 FBAT 0.015
BDNF rs7934165-rs1491850-rs1491851 251 FBAT 0.024
NTRK2 rs1147199-rs1025743-rs1187362 251 FBAT 0.039
SLC6A4 rs3794808-rs140701-rs140700 251 FBAT 0.033
SLC6A4 rs140701-rs140700-rs6354 251 FBAT 0.048
P2RX7 rs208290-rs208294-rs208298 251 FBAT 0.027
P2RX7 rs208290-rs208294-rs208298-rs504677 251 FBAT 0.011
P2RX7 rs208294-rs208298 251 FBAT 0.049
P2RX7 rs208294-rs208298-rs504677 251 FBAT 0.032
P2RX7 rs208294-rs208298-rs504677 251 FBAT 0.021
P2RX7 rs208294-rs208298-rs504677 251 FBAT 0.040
P2RX7 rs1718119-rs2230912 251 FBAT 0.045
P2RX7 rs1718119-rs2230912-rs2303998 251 FBAT 0.047
DISC1 rs1655285-rs751229 251 TRANSMIT 0.459
Broad SORCS2 rs4411993 298 FBAT 0.014
mood SORCS2 rs7683874 298 FBAT 0.008
disorder SORCS2 rs10937823 298 FBAT 0.004
DFNB31 rs10982256 298 FBAT 0.001
a Gene and variant associates also with cognitive traits.
Table continues
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5.2 Association analysis of six candidate genes  
 (II)
As discussed in the previous sections, linkage and association studies over the past 
years have highlighted several genomic regions of interest and focused attention 
on several potential candidate genes for bipolar disorder. However, none have 
yet been shown to be causative as have been for many non-psychiatric disorders 
(Craddock and Forty 2006; Serretti and Mandelli 2008). Recent GWAS and other 
studies in BP have strongly suggested that BP can result from the effects of multiple 
rare variants and that there are few, if any, common variants with large effect sizes 
on bipolar disorder risk (Ferreira et al. 2008; Scott et al. 2009). Therefore, genetic 
studies in isolated homogenous populations, such as the Finnish population, may 
be advantageous in identifying rare variants for BP. Other approaches are also 
required to disentangle conflicting findings, such as gene interaction analyses 
and endophenotype investigations. It is unclear which phenotype best captures 
the underlying mechanism of BP, and as a result the use of different phenotypic 
subtypes or endophenotypes, such as cognitive traits or the presence of psychotic 
symptoms, may be more appropriate phenotypes for study than DSM-diagnostic 
categories.
We wanted to examine in a family-based sample the roles in the genetic 
background of bipolar and psychotic disorders of the widely studied candidate 
genes from three seemingly distinct signalling systems that play regulatory roles 
in many neuronal functions: serotonin-related genes (SLC6A4 and TPH2), BDNF-
related genes (BDNF, CREB1 and NTRK2) and one gene related to the inflammation 
and cytokine system (P2RX7). In addition to diagnostic phenotypes, variants were 
tested to determine whether these candidate genes played possible aetiological roles 
in the genetic background of any related quantitative cognitive traits in Finnish BP 
families (Antila et al. 2007a). 
We investigated association of a total of 68 SNPs in the 723 individuals of the 
180 Finnish BP families. Consistent with earlier findings in other populations and 
samples, the functional variant Val66Met (rs6265) of BDNF was found to show a 
trend of association with bipolar spectrum disorder (p = 0.062; for only familial 
cases p = 0.016) as well as the variant at the 5’end of BDNF (p = 0.032 for rs1491851). 
The haplotype at the 5’ end of BDNF associated with bipolar spectrum disorder (p 
= 0.004 for haplotype T-C of rs1491850 and rs1491851, respectively). Association 
was seen between two variants of SLC6A4 (p = 0.045 for rs3794808 and p = 0.021 
for rs140700) and BP spectrum. However, the association was stronger in males 
than for the both genders (p = 0.007 for rs140700). Haplotype T-G of rs140700 
and rs6354 within SLC6A4 was associated stronger in males with bipolar spectrum 
disorder (p = 0.004; for both genders p = 0.017). In addition, a variant rs2230912 
within P2RX7 associated with BP spectrum (p = 0.048 with both genders, p = 0.038 
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for males). A four-SNP protective haplotype G-T-G-C of rs208290-rs208294-
rs208298-rs504677 showed the strongest association (p = 0.006 with both genders). 
We tested the association between the same variants that associated with 
dichotomous traits and quantitative traits derived from the neuropsychological 
test battery in 158 individuals from the bipolar families. The allele Val66 of BDNF 
associated with better performance in retention (p = 0.003) as well as the T-C 
haplotype of rs1491850 and rs1491851 (p = 0.0004). For the P2RX7 gene, a four-
SNP protective haplotype G-T-G-C of rs208290-rs208294-rs208298-rs504677 also 
showed relatively strong association with better performance in executive functions, 
and semantic and phonemic fluency (p = 0.006 and p = 0.0003, respectively). Better 
performance in semantic fluency was also associated with the C allele of rs504677 
(p = 0.0001). The variants in the 14th exon of NTRK2 associated with the most 
robust signal for recognition memory (rs7038236, rs11140796 and rs1221, p = 
0.0065, p = 0.005 and p = 0.0049, respectively) and auditory attention (rs1025743, 
p = 0.011).
The expression level of BDNF increases after antidepressant treatment (Duman 
and Monteggia 2006; Nibuya et al. 1995; Russo-Neustadt et al. 1999), which is 
the primary reason to suggest that it is a potential susceptibility gene for mood 
disorders. Association studies have repeatedly supported the evidence that BDNF is 
a susceptibility gene for mood disorders (Serretti and Mandelli 2008). Most studies 
have shown overtransmission of the common Valine allele (Geller et al. 2004; Green 
et al. 2006; Lohoff et al. 2005b; Neves-Pereira et al. 2002; Sklar et al. 2002; Strauss et 
al. 2004), but some studies have not detected association (Schumacher et al. 2005). 
Previous studies have strongly implicated a role of BDNF in cognitive functions, 
particularly in memory acquisition and consolidations (Martinowich and Lu 2008; 
Pang and Lu 2004; Tyler et al. 2002; Woo and Lu 2006). In the present study, we 
managed to replicate the association of the Valine allele with both BP and better 
performance in a memory test. The Val66Met variant lies within a large haplotype 
block, and thus it is difficult to identify which variant (possibly many) within 
the block is causative. The contradicting findings with the variants within BDNF 
suggest that this gene may contribute to specific aspects of BP, such as cognitive 
functions. Interestingly, we found that the NTRK2 gene, which is known as a 
BDNF-related gene, shows minor evidence of association with BP and recognition 
memory, further supporting the involvement of the BDNF signalling system in the 
genetic background of both bipolar and cognitive functions. However, CREB1 did 
not reveal any evidence of association with BP or cognitive functions. 
Serotonin-related genes, SLC6A4 and TPH2, are consistently associated with 
BP (Cho et al. 2005; Cichon et al. 2008; Grigoroiu-Serbanescu et al. 2008; Harvey 
et al. 2007; Harvey et al. 2004; Lopez et al. 2007; Roche and McKeon 2009; Van 
Den Bogaert et al. 2006). However, we did not found evidence of association with 
BP for the two functional variants of SLC6A4 and TPH2. Nonetheless, evidence 
of the association of a single variant and the two-SNP haplotype within SLC6A4 
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was found among BP males. In the present study, serotonin-related genes indicated 
association with the verbal working and immediate memory cognitive functions. 
We found significant associations of the variants within P2RX7 with BP and 
executive functions, particularly with semantic and phonemic fluency, which is 
proposed to be a good endophenotype for BP. Executive functions are found to 
be impaired in euthymic depression patients, and thus our finding may imply that 
variants within the gene associate with the depressive symptoms of BP patients. 
The function of P2RX7 in the central nervous system is only partly known. It has 
a known role in neurotransmitter release and inflammatory responses. It has been 
suggested that symptoms of depression are associated with increased immune 
activity and consequently the role of P2RX7 in BP might be more related to its 
immune function (Humphreys and Dubyak 1998). 
This study supports the involvement in Finnish BP families of BDNF, SLC6A4 
and P2RX7 in the genetic aetiology of BP by replicating previous findings as well 
as in the genetic background of cognitive traits. BDNF and its receptor NTRK2 
associate with verbal learning and memory and P2RX7 with executive function or 
fluency of thinking. 
5.3 Genome-wide linkage analysis
We conducted a genome-wide linkage scan for broad mood disorder using 5554 
autosomal SNPs in a family sample of 23 pedigrees originating from the late 
settlement region in Finland. Our aim was to identify loci that harbor susceptibility 
genes for broad mood disorder in our relatively homogenous set of BP families. We 
knew that we would not identify common risk variants, but hoped to find high risk 
variants that might be population specific. There were two regions, 9p13 and 7q31, 
that exceeded the LOD score of 3.0 (Z = 4.02 with rs716933 on 9p13, and Z =3.20 
with rs1510504 on 7q31). These chromosomal regions that exceeded a LOD score 
of 3.0 were analyzed by a haplotype and association analysis. For further linkage 
and association analyses, we used a larger set of 179 pedigrees including the initial 
23 families originating from the late settlement region.
In the initial sample of 23 families, the second best linkage result was rs1510504 
at 7q31.31 with a LOD score of 3.20. Furthermore, suggestive linkage was observed 
with the flanking markers rs1880180 (a LOD score of 2.06) and rs1419438 (a 
LOD score of 2.17), respectively 4.5 Mb and 8.2 Mb downstream from marker 
rs1510504. Eleven families originating from the late settlement region had a major 
influence on the linkage signal. The maximum multipoint NPL score using the set 
of six markers on 7q22.3-7q31.32 yielded a LOD score of 2.83. In the association 
analysis, marker rs342296 provided evidence of association (p = 0.00014). In 
addition, across the 7q22.2-7q35 region a two-SNP haplotype association revealed 
a risk haplotype A-G for rs1034761 and rs342296 (p = 0.0004, Table 15). 
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Potential bipolar candidate genes on the linkage region of chromosome 
7 include calcium-dependent activator protein for secretion 2 (CADPS2) and 
potassium-voltage-gated channel, member 2 (KCND2). CADPS2 is expressed in the 
nervous system, particularly in the cerebellum (Cisternas et al. 2003). Interestingly, 
cadps2 knockout mice have been observed to have defects in sleep-wake transitions 
and circadian rhythms. Sleep-wake cycles are often disrupted in BP and may be 
caused by the abnormalities in the circadian clock (Shi et al. 2008a). In addition, 
Cadps2 is involved in the release of neurotrophin-3 (NT-3) and brain-derived 
neurotrophic factor (BDNF) from neocortical and cerebellar neurons (Sadakata 
et al. 2007a; Sadakata et al. 2007b). KCND2 encodes a protein that forms voltage-
activated A-type potassium ion channels and is prominent in the repolarization of 
the action potential. It also has a role in the regulation of neurotransmitter release 
and in neuronal flexibility (Isbrandt et al. 2000; Zhu et al. 1999)
In the initial sample of 23 families, the most significant two-point LOD score 
(LOD = 4.02) was obtained at 9p13 with marker rs716933. Families from the late 
settlement region primarily contributed to the linkage, including the extended 
pedigree with the largest signal (LOD = 1.27). A maximum NPL score of 3.02 was 
revealed at marker rs716933 with a 7.8 cM interval around the marker showing a 
LOD score > 2.7. The linkage region spans the centromeric region, which contains 
intra- and interchromosomal duplications, including large blocks of duplications 
and a heterochromatin block (Humphray et al. 2004). Therefore, it is impossible to 
identify which side of the centromere the susceptibility region lies using the current 
set of markers. The centromeric region of the chromosome 9 harbors potential 
candidate genes, such as contacting associating protein-like 3 (CNTNAP3) and 
aldehyde dehydrogenase 1B1 precursor (ALDH1B1). CNTNAP3 encodes contactin-
associated protein 3 (Caspr3), which is a member of the neurexin superfamily 
that mediates neuron-glia interactions (Spiegel et al. 2002; Traut et al. 2006) and 
is expressed in the nervous system; cerebellum, caudate nucleus, hippocampus 
and sustantia nigra (Spiegel et al. 2002). The ALDH1B1 gene encodes aldehyde 
dehydrogenase protein, which belongs to the aldehyde dehydrogenase protein 
family that plays a major role in the detoxification of alcohol derived acetylaldehyde 
and is involved in the metabolism of corticosteroids and neurotransmitters 
(Vasiliou and Nebert 2005). Furthermore, the protein family is upregulated as part 
of the oxidative stress response, which has been implicated in the pathophysiology 
of BP (Machado-Vieira et al. 2007). In the haplotype association analysis a risk 
haplotype A-G of rs1220087 and rs666478, 1.11 Mb downstream from rs716933, 
showed the strongest signal (p = 0.00001). The region includes five genes, of which 
Phospholipase A2-activating protein (PLAP) regulates inflammatory response 
through its activation of phospholipase A2 (PLA2A), which was previously 
associated with BP in Caucasian families (Dawson et al. 1995; Jacobsen et al. 2001).
Six markers from the chromosome 7 linkage region and seven markers from 
the chromosome 9 linkage region were genotyped in a complete countrywide 
BP family sample, which comprised of 576 new individuals for a total of 723 
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individuals. For chromosome 7, the linkage signal declined to LOD <1.5 and the 
multipoint NPL score declined to NPL 1.40. The signal was thus derived mainly 
from the late settlement region families. For chromosome 9, a LOD score of 3.06 
was obtained with marker rs716933 using the complete set of families. However, no 
additional families showed strong evidence for linkage. 
In conclusion, we identified two chromosomal regions on 7q22.3–7q31.32 and 
9p21.3–9q13, of which 7q31 is a novel finding for broad mood disorders. Further 
analyses of the best markers in the complete set of 179 BP families supported the 
findings on chromosome 9p13. Because the majority of the linkage signal came from 
the late settlement families, including two extended families, and the signal was not 
replicated in the larger family sample, the signal may result from a rare variant 
with a large effect size in the locus. The 9p13 region harbors several interesting 
candidate genes for mood disorders, including CNTNAP3 and ALDH1B1. 
TABLE 15. Haplotype association results in 23 late settlement families for the 7q22.2–7q31.33 and 9p22.2–
q21.13 chromosomal regions. Results are given for the haplotype that gave the most significant P-value for each 
SNP pair. Bold SNP markers indicate a LOD >1.0 and bold p-values indicate p < 0.01.
Chromosome 7q22.2–7q31.33
SNPsa Distance (Mb)b Haplotype Frequency Z-valuec P-valued
rs234–rs41261
rs41261–rs176481
rs1024761–rs342296
rs342285–rs1476878
rs1476878–rs257376
rs43077–rs2040587
rs2040587–rs2056865
rs868053–rs12217
105.15–105.20
105.20–105.32
10.568–105.96
10596–106.29
106.29–106.39
111.83–114.26
114.26–115.81
120.37–121.30
AA
AG
AG
GG
GA
GG
AG
AG
0.233
0.323
0.206
0.224
0.194
0.214
0.141
0.261
2.688
2.768
3.538
2.918
2.409
2.222
-2.183
2.013
0.007
0.005
0.0004
0.003
0.016
0.026
0.029
0.044
Chromosome 9q22.2–9q21.13
SNPsa Position (Mb)b Haplotype Frequency Z-valuec P-valued
rs1327063–rs702223
rs757099–rs1220087
rs1220087–rs666478
rs666478–rs1555454
rs1475656–rs1412340
rs1412340–rs288886
rs288886–rs671018
rs671018–rs855543
rs855543–rs471371
rs1138374–rs716933
rs716933–rs1004604
rs1004604–rs987187
rs1074670–rs1404195
22.35–23.82
25.72–25.77
25.77–27.16
27.16–27.21
30.9–31.6
31.6–31.73
31.73–32.55
32.55–33.63
33.63–33.86
37.96–38.32
38.32–38.35
38.35–38.36
71.24–71.61
CC
AG
AG
GA
AA
GA
GG
GA
GA
GA
GA
AG
GA
0.241
0.462
0.225
0.506
0.139
0.149
0.329
0.246
0.279
0.215
0.340
0.569
0.200
-2.184
-1.978
4.405
3.218
-2.063
2.404
-2.202
-2.776
2.099
3.230
-2.655
-2.101
2.147
0.028
0.047
0.00001
0.001
0.0.39
0.016
0.027
0.005
0.035
0.001
0.007
0.035
0.031
a Haplotypes were calculated by the sliding window method of 2-SNPs. Associating haplotypes of 2-SNPs were analyzed 
as extended 3-SNP haplotypes. Haplotypes were analyzed between markers giving LOD scores above1.5 (in bold) as well 
as five flanking markers downstream and upstream of the significant marker.
b The position of the SNP is according to the May 2004 human reference sequence (NCBI Build 35)
c A negative Z-statistic score indicates a protective haplotype and positive score indicates a risk haplotype.
d FBAT p-values are obtained with the HBAT option.
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5.4 Genome-wide association replicate   
 analysis (IV)
Recent genome-wide association studies have provided multiple variants that 
yielded consistent association with complex disorders, such as type 2 diabetes (The 
Wellcome Trust Case Control Consortium 2007). Three groups have performed 
independent GWAS of bipolar disorder using either pooled (Baum et al 2008) or 
individually genotyped samples (The Wellcome Trust Case Control Consortium 
2007, Sklar et al.2008). However, there has been a lack of overlap between these 
studies for their most significant results; only a small amount of findings are shared 
(Baum and Hamsphere 2008). Part of the lack of overlap can be explained by 
different study designs, genetic heterogeneity difficulties in detecting rare alleles 
and/or the small effects of variants on BP risk. In addition, difficulties in diagnosis 
and the lack of specific quantitative biological markers render mapping more 
challenging. In this study our aim was to evaluate the role of associating variants 
from three bipolar GWA studies in Finnish bipolar families. 
We have analyzed in 723 individuals of 180 Finnish BP families the most 
significantly associating variants from the Wellcome Trust Case Control 
Consortium (The Wellcome Trust Case Control Consortium 2007), Baum et al. 
(Baum et al 2008) and a meta-analysis (Baum and Hamsphere 2008). The most 
strongly associating SNPs of p-values p < 0.0001 and p < 0.000054 were selected 
from Baum et al. and WTCCC, respectively. SNPs located in the lithium pathway 
genes were also selected for the present study. Altogether 26 SNPs were genotyped 
and analyzed using two diagnostic categories: bipolar type I disorder and broad 
mood disorder i.e. bipolar type I, II, NOS and cyclothymia. 
We found consistent evidence supporting the previously reported DFNB31, 
SORCS2, SCL39A4 and DGKH findings. For both diagnostic categories, we found 
three SNPs in SORCS2 associating significantly (p = 0.014–0.0041). Two of these 
variants were allelic replications and represented the same signal according to 
haplotype analysis. SORCS2 is expressed in the central nervous system and encodes 
a receptor in the synaptic signal system. The best association was found with one 
variant of DFNB31 (p = 0.00012 for broad mood disorder and p = 0.0097 for bipolar 
type I disorder) that remained significant after correction for multiple testing. 
DFNB31 is also strongly expressed in the central nervous system and is involved in 
synaptic transmission. Interestingly, mutation in this gene causes a recessive form 
of hearing loss. With bipolar type I disorder as an outcome, we found a signal for 
association with an allelic variant of SLC39A4 (p = 0.034). However, we did not 
find support for the PLAB2 association, which was the most significant result in 
the WTCCC GWAS. 
In conclusion, this replication revealed significant association with four genes 
previously associated with BP, and thus supports their role as predisposing genes 
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in the aetiology of BP and other psychiatric diseases. The present replication may 
give us a hint of the pathways involved in the development of bipolar and related 
psychiatric disorders.
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6	 Concluding	remarks	and	future		
	 prospects
BP has a strong genetic component. Nonetheless, the underlying genetic and 
pathophysiological inducers of the disorder remain elusive. Intensive genetic 
research of BP, including multiple linkage and candidate gene studies, have 
revealed several regions of interest as well as evidence implicating particular genes, 
but no loci or genes have been convincingly identified. The pessimistic view, that 
psychiatric genetics is so complex that advances are unlikely, has been common 
in the past decades. However, in the last few years numerous improvements in the 
molecular genetics research, including technical and statistical developments, have 
facilitated the studies of complex disorders. The aim of this thesis was to investigate 
the genetic basis of BP and to identify genetic variants that increase susceptibility 
to BP and its related cognitive endophenotypes in the Finnish families. In reference 
to the aims of this thesis study, the following findings are presented:
1.  In the association study of the TSNAX/DISC1 gene cluster, support was 
found for the involvement of DISC1 in the genetic aetiology of BP. Distinct 
allelic variants contribute to variation in the psychotic and bipolar spectrum 
disorders in Finnish BP families. The variants included in these associating 
haplotypes also displayed association with different cognitive traits, proposing 
possible systems underlying the biology of BP. 
2.  The association study supports the involvement of BDNF, SLC6A4 and P2RX7 
in the genetic aetiology of BP through replication of previous findings. The 
genes also showed contribution to the genetic background of cognitive traits 
in Finnish BP families. BDNF and its receptor NTRK2 associate with verbal 
learning and memory and P2RX7 with executive function or fluency of 
thinking. 
3.  In the genome-wide linkage scan, two chromosomal regions on 7q22.3-
7q31.32 and 9p21.3-9q13 showed evidence for linkage. Chromosome 7q31 
appears to be a novel finding for broad mood disorders. Further analyses in 
the complete set of BP families supported the findings on chromosome 9p13. 
The majority of the linkage signal came from the late settlement families, 
suggesting that the signal may result from a rare variant with a large effect size 
in these families. 
4. In the genome-wide association replication analysis, six associating SNPs 
in the DFNB31, SORCS2, SLC39A3 and DGKH genes replicated the recent 
GWAS findings in the Finnish BP families. These findings further support the 
involvement of these genes and their pathways in the biology of BP. 
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The most promising linkage findings on chromosome 9p13 in the present study 
suggest the identification of a BP susceptibility region. A future task is to define the 
underlying causative variants in that highly duplicated region by more sophisticated 
CNV analysis and sequencing the most promising regions. In addition, the 
promising association findings of the DISC1/TSNAX, DFNB31 and SORCS2 genes 
in the present study suggest involvement of these genes in the aetiology of BP. 
Therefore, sequencing these genes may expose causative variants in the Finnish 
population. Recent genome-wide studies have identified many common variants 
that are associated with complex disorders, providing new opportunities to explore 
their biological bases. For BP, GWAS and other studies strongly suggest that BP 
results from the effects of multiple rare variants and that there are only a few common 
variants that can be unequivocally identified in various study populations. Allelic 
heterogeneity has the potential to have important roles in the genetic aetiology of 
disorders, but it is difficult to detect in population based-samples using the common 
variants often genotyped. In order to fully understand the allelic heterogeneity that 
underlies common diseases, complete genome sequencing for many individuals 
with and without disease is required. Therefore, it is likely that most of the genetic 
variants increasing risk for BP remain to be discovered.
The identification of risk variants has the potential to help improve the 
understanding of BP pathophysiology.  The roles of epigenetic factors, rare variants 
and copy number variants are important targets for future BP genetic research. 
Since epigenetic mechanisms increase the complexity of genomic responses by 
allowing for both short- and long term modifications of the genome, they provide 
a mechanism for preserving information on environmental exposures. BP may 
be due to a combination of multiple common variants with relatively small effect 
sizes, a few rare variants with larger effect sizes, structural variations such as CNVs 
and epigenetic modifications. The identification of susceptibility genes will also 
facilitate the development of treatments better targeted at the biochemical level. 
In addition, it will further facilitate the identification of environmental factors 
that alter risk.  Once the aetiological factors are characterized, it may be possible 
to provide genetically- and environmentally-tailored occupational, social and 
psychological advice to individuals with a high risk of mood disorders.
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